+

WO1999014327A2 - Genes amplifies dans des tumeurs, anticorps diriges contre les proteines codees par ces genes, et leur utilisation dans le diagnostic et le traitement du cancer - Google Patents

Genes amplifies dans des tumeurs, anticorps diriges contre les proteines codees par ces genes, et leur utilisation dans le diagnostic et le traitement du cancer Download PDF

Info

Publication number
WO1999014327A2
WO1999014327A2 PCT/US1998/018824 US9818824W WO9914327A2 WO 1999014327 A2 WO1999014327 A2 WO 1999014327A2 US 9818824 W US9818824 W US 9818824W WO 9914327 A2 WO9914327 A2 WO 9914327A2
Authority
WO
WIPO (PCT)
Prior art keywords
pro240
pro230
ebaf
antibody
polypeptide
Prior art date
Application number
PCT/US1998/018824
Other languages
English (en)
Other versions
WO1999014327A3 (fr
Inventor
David Botstein
Audrey Goddard
Austin Gurney
Kenneth Hillan
David A. Lawrence
Margaret Roy
William I. Wood
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to AU93121/98A priority Critical patent/AU9312198A/en
Publication of WO1999014327A2 publication Critical patent/WO1999014327A2/fr
Priority to JP2000570204A priority patent/JP2003524380A/ja
Priority to CA002341304A priority patent/CA2341304A1/fr
Priority to PCT/US1999/020594 priority patent/WO2000015666A2/fr
Priority to IL14142699A priority patent/IL141426A0/xx
Priority to AU58167/99A priority patent/AU5816799A/en
Priority to EP99945592A priority patent/EP1109833A2/fr
Priority to KR1020017003085A priority patent/KR20010103576A/ko
Priority to MXPA01002545A priority patent/MXPA01002545A/es
Publication of WO1999014327A3 publication Critical patent/WO1999014327A3/fr
Priority to US09/828,366 priority patent/US20020010137A1/en
Priority to US09/902,692 priority patent/US20030054400A1/en
Priority to US09/902,634 priority patent/US20030082540A1/en
Priority to US09/902,572 priority patent/US20030108983A1/en
Priority to US09/902,736 priority patent/US20030049676A1/en
Priority to US09/902,615 priority patent/US20030092002A1/en
Priority to US09/902,853 priority patent/US20020192659A1/en
Priority to US09/902,979 priority patent/US20030113718A1/en
Priority to US09/902,713 priority patent/US20030082541A1/en
Priority to US09/902,759 priority patent/US20030077654A1/en
Priority to US09/902,903 priority patent/US20030044839A1/en
Priority to US09/903,562 priority patent/US6965015B2/en
Priority to US09/903,603 priority patent/US20030148419A1/en
Priority to US09/903,943 priority patent/US20030054349A1/en
Priority to US09/903,640 priority patent/US7208308B2/en
Priority to US09/903,786 priority patent/US20030044793A1/en
Priority to US09/903,520 priority patent/US20030054401A1/en
Priority to US09/903,806 priority patent/US20030130489A1/en
Priority to US09/904,119 priority patent/US20030049621A1/en
Priority to US09/903,925 priority patent/US20030096233A1/en
Priority to US09/903,749 priority patent/US7147853B2/en
Priority to US09/903,823 priority patent/US20030104381A1/en
Priority to US09/904,011 priority patent/US20030003530A1/en
Priority to US09/904,938 priority patent/US20030211569A1/en
Priority to US09/904,786 priority patent/US7557192B2/en
Priority to US09/905,125 priority patent/US6664376B2/en
Priority to US09/905,088 priority patent/US20030073077A1/en
Priority to US09/904,859 priority patent/US20030036060A1/en
Priority to US09/905,056 priority patent/US20030054441A1/en
Priority to US09/904,992 priority patent/US20030135025A1/en
Priority to US09/905,291 priority patent/US20020160374A1/en
Priority to US09/904,877 priority patent/US20030186358A1/en
Priority to US09/904,766 priority patent/US20030152999A1/en
Priority to US09/904,838 priority patent/US20030148370A1/en
Priority to US09/905,075 priority patent/US7169906B2/en
Priority to US09/904,553 priority patent/US20030059828A1/en
Priority to US09/904,462 priority patent/US6878807B2/en
Priority to US09/904,532 priority patent/US7151160B2/en
Priority to US09/905,449 priority patent/US6965011B2/en
Priority to US09/904,920 priority patent/US6806352B2/en
Priority to US09/905,348 priority patent/US20030064923A1/en
Priority to US09/904,820 priority patent/US20030036094A1/en
Priority to US09/905,381 priority patent/US6818746B2/en
Priority to US09/904,485 priority patent/US20030064367A1/en
Priority to US09/904,956 priority patent/US20030049622A1/en
Priority to US09/906,646 priority patent/US6852848B2/en
Priority to US09/906,700 priority patent/US6723535B2/en
Priority to US09/906,760 priority patent/US20030096340A1/en
Priority to US09/906,679 priority patent/US6974689B1/en
Priority to US09/906,742 priority patent/US20030023054A1/en
Priority to US09/906,777 priority patent/US20030148371A1/en
Priority to US09/906,815 priority patent/US7094567B2/en
Priority to US09/906,838 priority patent/US7070979B2/en
Priority to US09/906,618 priority patent/US6828146B2/en
Priority to US09/906,722 priority patent/US6946262B2/en
Priority to US09/907,925 priority patent/US20030054352A1/en
Priority to US09/907,728 priority patent/US20030190611A1/en
Priority to US09/907,979 priority patent/US20030082542A1/en
Priority to US09/908,093 priority patent/US20030017498A1/en
Priority to US09/907,613 priority patent/US20030027145A1/en
Priority to US09/907,824 priority patent/US20020197671A1/en
Priority to US09/907,575 priority patent/US20030073079A1/en
Priority to US09/907,841 priority patent/US7033825B2/en
Priority to US09/907,652 priority patent/US20030104469A1/en
Priority to US09/907,942 priority patent/US7087738B2/en
Priority to US09/907,794 priority patent/US6635468B2/en
Priority to US09/909,204 priority patent/US20030036061A1/en
Priority to US09/908,576 priority patent/US20040005553A1/en
Priority to US09/909,088 priority patent/US20020146709A1/en
Priority to US09/909,320 priority patent/US7074592B2/en
Priority to US09/909,064 priority patent/US6818449B2/en
Priority to US10/002,796 priority patent/US20030032057A1/en
Priority to US10/001,054 priority patent/US20020192209A1/en
Priority to US10/028,072 priority patent/US20030004311A1/en
Priority to US10/066,203 priority patent/US20030180796A1/en
Priority to US10/066,500 priority patent/US20020177165A1/en
Priority to US10/066,269 priority patent/US20030040014A1/en
Priority to US10/066,198 priority patent/US20030170721A1/en
Priority to US10/066,273 priority patent/US7317092B2/en
Priority to US10/066,211 priority patent/US20030044844A1/en
Priority to US10/081,056 priority patent/US20040043927A1/en
Priority to US10/119,480 priority patent/US20040087769A1/en
Priority to US10/121,046 priority patent/US20030194791A1/en
Priority to US10/121,059 priority patent/US20030190721A1/en
Priority to US10/121,045 priority patent/US20030073210A1/en
Priority to US10/121,047 priority patent/US20030077778A1/en
Priority to US10/121,042 priority patent/US20030096386A1/en
Priority to US10/121,040 priority patent/US20030082759A1/en
Priority to US10/121,044 priority patent/US20030190717A1/en
Priority to US10/121,051 priority patent/US20030092147A1/en
Priority to US10/121,041 priority patent/US20030077776A1/en
Priority to US10/121,056 priority patent/US20030082760A1/en
Priority to US10/121,061 priority patent/US20030082761A1/en
Priority to US10/121,062 priority patent/US20030077779A1/en
Priority to US10/121,052 priority patent/US20030199052A1/en
Priority to US10/121,063 priority patent/US20030199055A1/en
Priority to US10/121,050 priority patent/US20030054516A1/en
Priority to US10/121,055 priority patent/US20030190718A1/en
Priority to US10/121,057 priority patent/US20030190719A1/en
Priority to US10/121,058 priority patent/US20030190720A1/en
Priority to US10/121,048 priority patent/US20030199051A1/en
Priority to US10/121,054 priority patent/US20030199054A1/en
Priority to US10/121,053 priority patent/US20030199053A1/en
Priority to US10/121,043 priority patent/US7220831B2/en
Priority to US10/121,049 priority patent/US20030022239A1/en
Priority to US10/121,060 priority patent/US20030190722A1/en
Priority to US10/123,236 priority patent/US20030068795A1/en
Priority to US10/123,155 priority patent/US20030068794A1/en
Priority to US10/123,771 priority patent/US20030199060A1/en
Priority to US10/123,213 priority patent/US7193048B2/en
Priority to US10/123,108 priority patent/US7635478B2/en
Priority to US10/123,214 priority patent/US7343721B2/en
Priority to US10/123,157 priority patent/US20030190725A1/en
Priority to US10/123,213 priority patent/US20030199057A1/en
Priority to US10/123,322 priority patent/US20030199059A1/en
Priority to US10/123,156 priority patent/US20030194792A1/en
Priority to US10/123,215 priority patent/US7291329B2/en
Priority to US10/123,235 priority patent/US20030082762A1/en
Priority to US10/123,291 priority patent/US20030199058A1/en
Priority to US10/123,212 priority patent/US7276577B2/en
Priority to US10/123,154 priority patent/US20030190724A1/en
Priority to US10/123,261 priority patent/US20030068796A1/en
Priority to US10/123,262 priority patent/US20030049816A1/en
Priority to US10/123,109 priority patent/US20030190723A1/en
Priority to US10/123,292 priority patent/US20030073211A1/en
Priority to US10/123,909 priority patent/US7193049B2/en
Priority to US10/123,910 priority patent/US7329404B2/en
Priority to US10/123,906 priority patent/US20030190726A1/en
Priority to US10/123,902 priority patent/US20030077781A1/en
Priority to US10/123,904 priority patent/US20030022328A1/en
Priority to US10/123,913 priority patent/US20030203462A1/en
Priority to US10/123,905 priority patent/US20030087344A1/en
Priority to US10/123,903 priority patent/US20030073212A1/en
Priority to US10/123,907 priority patent/US7084258B2/en
Priority to US10/123,905 priority patent/US7285625B2/en
Priority to US10/123,912 priority patent/US20030100087A1/en
Priority to US10/123,908 priority patent/US7335728B2/en
Priority to US10/123,911 priority patent/US7408032B2/en
Priority to US10/124,814 priority patent/US7105335B2/en
Priority to US10/124,821 priority patent/US20030199023A1/en
Priority to US10/124,817 priority patent/US20030077786A1/en
Priority to US10/125,805 priority patent/US20030194794A1/en
Priority to US10/125,704 priority patent/US7357926B2/en
Priority to US10/124,819 priority patent/US7285626B2/en
Priority to US10/124,823 priority patent/US20030199062A1/en
Priority to US10/124,818 priority patent/US20030082763A1/en
Priority to US10/124,822 priority patent/US7109305B2/en
Priority to US10/124,820 priority patent/US20030190729A1/en
Priority to US10/125,795 priority patent/US7304131B2/en
Priority to US10/124,824 priority patent/US20030077659A1/en
Priority to US10/124,816 priority patent/US20030190728A1/en
Priority to US10/124,813 priority patent/US7312307B2/en
Priority to US10/125,924 priority patent/US7342097B2/en
Priority to US10/125,922 priority patent/US7309762B2/en
Priority to US10/125,931 priority patent/US20030199063A1/en
Priority to US10/125,927 priority patent/US20030190731A1/en
Priority to US10/125,932 priority patent/US7317079B2/en
Priority to US10/127,831 priority patent/US20030082689A1/en
Priority to US10/128,689 priority patent/US20030087365A1/en
Priority to US10/131,817 priority patent/US7291701B2/en
Priority to US10/131,825 priority patent/US7282566B2/en
Priority to US10/131,823 priority patent/US7304132B2/en
Priority to US10/137,865 priority patent/US20030032155A1/en
Priority to US10/137,868 priority patent/US20030082764A1/en
Priority to US10/137,867 priority patent/US20030207349A1/en
Priority to US10/140,023 priority patent/US20030207416A1/en
Priority to US10/139,980 priority patent/US7247710B2/en
Priority to US10/140,020 priority patent/US20030207415A1/en
Priority to US10/139,963 priority patent/US7288625B2/en
Priority to US10/140,024 priority patent/US20040058424A1/en
Priority to US10/140,470 priority patent/US20030022331A1/en
Priority to US10/140,474 priority patent/US20030032156A1/en
Priority to US10/140,860 priority patent/US7307151B2/en
Priority to US10/140,921 priority patent/US7317080B2/en
Priority to US10/140,925 priority patent/US20030073215A1/en
Priority to US10/140,928 priority patent/US20030068798A1/en
Priority to US10/140,809 priority patent/US20030207418A1/en
Priority to US10/140,864 priority patent/US20030207419A1/en
Priority to US10/140,805 priority patent/US20030207417A1/en
Priority to US10/140,808 priority patent/US7425621B2/en
Priority to US10/140,865 priority patent/US20030207420A1/en
Priority to US10/141,760 priority patent/US7342104B2/en
Priority to US10/141,701 priority patent/US20030207421A1/en
Priority to US10/141,754 priority patent/US7361732B2/en
Priority to US10/141,755 priority patent/US7297764B2/en
Priority to US10/141,756 priority patent/US7488586B2/en
Priority to US10/142,425 priority patent/US20030207424A1/en
Priority to US10/142,417 priority patent/US7304133B2/en
Priority to US10/142,430 priority patent/US7309766B2/en
Priority to US10/143,114 priority patent/US20030036180A1/en
Priority to US10/143,113 priority patent/US7329730B2/en
Priority to US10/142,419 priority patent/US7153941B2/en
Priority to US10/143,032 priority patent/US7408033B2/en
Priority to US10/142,431 priority patent/US7285629B2/en
Priority to US10/142,423 priority patent/US20030049817A1/en
Priority to US10/146,730 priority patent/US20030207427A1/en
Priority to US10/146,792 priority patent/US20030207428A1/en
Priority to US10/147,528 priority patent/US20030219885A1/en
Priority to US10/147,536 priority patent/US20040077064A1/en
Priority to US10/147,492 priority patent/US20030082765A1/en
Priority to US10/147,519 priority patent/US20030077791A1/en
Priority to US10/152,395 priority patent/US7189534B2/en
Priority to US10/153,934 priority patent/US20030129695A1/en
Priority to US10/156,843 priority patent/US20030207805A1/en
Priority to US10/157,786 priority patent/US20030208055A1/en
Priority to US10/157,782 priority patent/US20030077792A1/en
Priority to US10/160,498 priority patent/US20030073216A1/en
Priority to US10/158,791 priority patent/US20030207429A1/en
Priority to US10/158,782 priority patent/US20030082766A1/en
Priority to US10/176,913 priority patent/US20030022298A1/en
Priority to US10/197,942 priority patent/US20030175882A1/en
Priority to US10/215,371 priority patent/US20040137561A1/en
Priority to US10/963,467 priority patent/US7223586B2/en
Priority to US10/970,823 priority patent/US7307152B2/en
Priority to US11/050,559 priority patent/US7157267B2/en
Priority to US11/080,062 priority patent/US7619062B2/en
Priority to US11/081,485 priority patent/US20050170465A1/en
Priority to US11/240,891 priority patent/US20060246540A1/en
Priority to US11/341,175 priority patent/US7468427B2/en
Priority to US11/353,554 priority patent/US7417126B2/en
Priority to US11/355,441 priority patent/US7449551B2/en
Priority to US11/518,609 priority patent/US20070077623A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • the present invention relates to compositions and methods for the diagnosis and treatment of tumor.
  • Malignant tumors are the second leading cause of death in the United States, after heart disease (Boring et al.. CA Cancel J. Clin. 43. 7,[1993]).
  • Cancer is characterized by the increase in the number of abnormal, or neoplastic, cells derived from a normal tissue which proliferate to form a tumor mass, the invasion of adjacent tissues by these neoplastic tumor cells, and the generation of malignant cells which eventually spread via the blood or lymphatic system to regional lymph nodes and to distant sites (metastasis). In a cancerous state a cell proliferates under conditions in which normal cells would not grow. Cancer manifests itself in a wide variety of forms, characterized by different degrees of invasiveness and aggressiveness.
  • a well known mechanism of gene (e.g. oncogene) overexpression in cancer cells is gene amplification. This is a process where in the chromosome of the ancestral cell multiple copies of a particular gene are produced. The process involves unscheduled replication of the region of chromosome comprising the gene, followed by recombination of the replicated segments back into the chromosome (Alitalo et al.. Adv. Cancer Res.47.235-281 [1986]). It is believed that the overexpression of the gene parallels gene amplification, i.e. is proportionate to the number of copies made.
  • Proto-oncogenes that encode growth factors and growth factor receptors have been identified to play important roles in the pathogenesis of various human malignancies, including breast cancer.
  • the human ErbB2 gene erbB2, also known as her2, or c-erbB-2
  • c-erbB-2 which encodes a 185-kd transmembrane glycoprotein receptor (pi 85TM ⁇ , HER2) related to the epidermal growth factor receptor (EGFR)
  • EGFR epidermal growth factor receptor
  • erbB2 overexpression is commonly regarded as a predictor of a poor prognosis, especially in patients with primary disease that involves axillary lymph nodes (Slamon et al, [1987] and [1989], supra; Ravdin and Chamness, Gene 159:19-27 [1995]; and Hynes and Stern, Biochim Biophys Acta 1198: 165-184 [1994]), and has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate. and fluoruracil) and anthracychnes (Baselga et al. Oncology 11(3 Suppl l):43-48 [1997]).
  • CMF cyclophosphamide, methotrexate. and fluoruracil
  • anthracychnes Baselga et al. Oncology 11(3 Suppl l):43-48 [1997]).
  • HER2-positive patients responding clinically to treatment with taxanes were greater than three times those of HER2-negative patients (Ibid).
  • a recombinant humanized anti-ErbB2 (anti-HER2) monoclonal antibody (a humanized version of the murine anti-ErbB2 antibody 4D5, referred to as rhuMAb HER2 or Herceptin®) has been clinically active in patients with ErbB2-overexpressing metastatic breast cancers that had received extensive prior anticancer therapy. (Baselga et al, J. Clin. Oncol. 14:737-744 [1996]).
  • the present invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans.
  • the present invention is based on the identification of genes that are amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, and may act of predictors of the prognosis of tumor treatment.
  • the present invention concerns an isolated antibody which binds a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • the antibody induces death of a cell overexpressing a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • the antibody is a monoclonal antibody, which preferably has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues.
  • CDR complementarity determining region
  • FR human framework region
  • the antibody may be labeled and may be immobilized on a solid support.
  • the antibody is an antibody fragment, a single-chain antibody, or an anti-idiotypic antibody.
  • the invention concerns a composition
  • a composition comprising an antibody which binds a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide in admixture with a pharmaceutically acceptable carrier.
  • the composition comprises a therapeutically effective amount of the antibody.
  • the composition comprises a further active ingredient, which may, for example, be a further antibody or a cytotoxic or chemotherapeutic agent.
  • the composition is sterile.
  • the invention concerns nucleic acid encoding an anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibody, and vectors and recombinant host cells comprising such nucleic acid.
  • the invention concerns a method for producing an anti-PROl 87,
  • PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibody by culturing a host cell transformed with nucleic acid encoding the antibody under conditions such that the antibody is expressed, and recovering the antibody from the cell culture.
  • the invention further concerns antagonists and agonists of a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, orEBAF-2 polypeptide that inhibit one or more of the functions or activities of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • the invention concerns isolated nucleic acid molecules that hybridize to the complement of the nucleic acid molecules encoding the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptides.
  • the nucleic acid preferably is DNA. and hybridization preferably occurs under stringent conditions.
  • Such nucleic acid molecules can act as antisense molecules of the amplified genes identified herein, which, in turn, can find use in the modulation of the respective amplified genes, or as antisense primers in amplification reactions.
  • sequences can be used as part of ribozyme and/or triple helix sequence which, in turn, may be used in regulation of the amplified genes.
  • the invention concerns a method for determining the presence of a
  • PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide comprising exposing a cell suspected of containing the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide to an anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibody and determining binding of the antibody to the cell.
  • the present invention concerns a method of diagnosing tumor in a mammal, comprising detecting the level of expression of a gene encoding a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher expression level in the test sample indicates the presence of tumor in the mammal from which the test tissue cells were obtained.
  • the present invention concerns a method of diagnosing tumor in a mammal, comprising (a) contacting an anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibody with a test sample of tissue cells obtained from the mammal , and (b) detecting the formation of acomplex between the anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibody and the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide in the test sample.
  • the detection may be qualitative or quantitative, and may be performed in comparison with monitoring the complex formation in a control sample of known normal tissue cells of the same cell type. A larger quantity of complexes formed in the test sample indicates the presence of tumor in the mammal from which the test tissue cells were obtained.
  • the antibody preferably carries a detectable label. Complex formation can be monitored, for example, by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art.
  • test sample is usually obtained from an individual suspected to have neoplastic cell growth or proliferation (e.g. cancerous cells).
  • the present invention concerns a cancer diagnostic kit, comprising an anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibody and a carrier (e.g. a buffer) in suitable packaging.
  • the kit preferably contains instructions for using the antibody to detect the PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • the invention concerns a method for inhibiting the growth of tumor cells comprising exposing a cell which overexpresses a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261 , PR0246, or EBAF-2 polypeptide to an effective amount of an agent inhibiting the expression and/or activity of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • the agent preferably is an anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibody, a small organic and inorganic molecule, peptide, phosphopeptide, antisense or ribozyme molecule, or a triple helix molecule.
  • the agent e.g. anti-PR0187, PR0533, PR0214, PRO240, PR021 1 , PRO230, PR0261, PR0246, or EBAF-2 antibody induces cell death.
  • the tumor cells are further exposed to radiation treatment and/or a cytotoxic or chemotherapeutic agent.
  • the invention concerns an article of manufacture, comprising: a container; a label on the container; and a composition comprising an active agent contained within the container; wherein the composition is effective for inhibiting the growth of tumor cells, the label on the container indicates that the composition can be used for treating conditions characterized by overexpression of a PR0187, PR0533, PR0214, PRO240, PR0211 , PR0230, PR0261 , PR0246, or EB AF-2 polypeptide, and the active agent in the composition is an agent inhibiting the expression and/or activity of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • the active agent is an anti-PR0187, PR0533, PR0214, PRO240, PR021 1, PRO230, PR0261, PR0246, or EBAF-2 antibody.
  • a method for identifying a compound capable of inhibiting the expression and/or activity of a PRO 187, PR0533, PR0214, PRO240, PR021 1, PRO230, PR0261 , PR0246, or EBAF-2 polypeptide comprising contacting a candidate compound with a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide under conditions and for a time sufficient to allow these two components to interact.
  • either the candidate compound or the PR0187, PR0533, PR0214, PRO240, PR021 1 , PRO230, PR0261, PR0246, or EBAF-2 polypeptide is immobilized on a solid support.
  • the non-immobilized component carries a detectable label.
  • SEQ ID NO: 1 shows the nucleotide sequence of DNA27864 that is a cDNA encoding a native sequence FGF-8 homologue (PRO 187).
  • Figure 2 shows the derived amino acid sequence of a native sequence FGF-8 homologue (PRO 187).
  • Figure 3 describes the Blast score, match and percent homology alignment between the sequence of DNA26645 (SEQ ID NO: 3; a virtual sequence used in the isolation of DNA27864) and the GenBank sequence S78462S3 (SEQ ID NO: 4).
  • Figure 4 demonstrates the specific binding of PR0533 (UNQ334) encoded by DNA49435 to FGF Receptor 3 (FGFR3).
  • Figure 5 shows the single stranded nucleotide sequence of a native sequence DNA49435 cDNA (SEQ ID NO: 5).
  • Figure 6 shows the derived amino acid sequence of a native sequence PR0533 FGF homologue polypeptide (SEQ ID NO: 6).
  • Figure 7 describes the Blast score, match and percent homology alignment between amino acid residues 3 to 216 of PR0533 (SEQ ID NO: 6) encoded by DNA49435 with residues 6 to 218 of AF007268 , a fibroblast growth factor sequence (SEQ ID NO: 7).
  • Figure 8 shows AF007268, an FGF- 15 EST sequence (SEQ ID NO: 8) which was used to search various public EST databases (e.g., GenBank, Dayhoff, etc.).
  • Figure 9 shows the nucleotide sequence of a native sequence EGF-like homologue cDNA DNA32286 (SEQ ID NO: 9).
  • Figure 10 shows the derived amino acid sequence of a native sequence EGF-like homologue (PR0214; SEQ ID NO: 10) as encoded by the coding sequence of Fig. 9.
  • Figure 1 1 shows the nucleotide sequence (SEQ ID NO: 11) of a native sequence PRO240 cDNA, wherein the nucleotide sequence is designated herein as "UNQ214" and/or "DNA34387".
  • Figure 12 shows the amino acid sequence (PRO240; SEQ ID NO: 12) derived from the nucleotide sequence shown in Figure 11.
  • Figure 13 shows the consensus nucleotide sequence designated "DNA30873" (SEQ ID NO: 13) derived from a variety of expressed sequence tags (EST's).
  • Figure 14 shows a BLAST sequence alignment analysis of a portion of the PRO240 amino acid sequence derived from the DNA34387 molecule (“DNA34387”) (SEQ ID NO: 14) with the serrate protein precursor from Drosophilia melanogaster (“SERR_DROME) (SEQ ID NO: 15).
  • Figure 15 shows a BLAST sequence alignment analysis of a portion of the PRO240 amino acid sequence derived from the DNA34387 molecule (“DNA34387”) (SEQ ID NO: 16) with the C-serrate-1 protein of Gallus gallus (“GGCSERRATJ ”) (SEQ ID NO: 17).
  • Figure 16 shows the nucleotide sequence (SEQ ID NO: 18) of a native sequence EGF-like homologue (designated "DNA32292").
  • Figure 17 shows the amino acid sequence (PR0211 ; SEQ ID NO: 19) derived from the nucleotide sequence shown in Figure 16.
  • Figure 18 shows the amino acid sequence (SEQ ID NO: 20) of PRO230 derived from the nucleotide sequence "DNA33223".
  • Figure 19 shows the consensus nucleotide sequence "DNA30857” (SEQ ID NO: 21) derived from the alignment of nucleotide sequence from a variety of expressed sequence tags (ESTs).
  • Figure 20 shows the nucleotide sequence (SEQ ID NO: 22) of a native sequence PRO230 cDNA, wherein the nucleotide sequence is designated herein as "DNA33223". As used herein, “DNA33223” is used interchangeably with "UNQ204".
  • Figure 21 shows an amino acid sequence alignment of PRO230 (residues 44-463; SEQ ID NO: 23) with a portion of a rabbit tubulointerstitial nephritis antigen precursor (SEQ ID NO: 24).
  • Figure 22 shows a nucleotide sequence (SEQ ID NO: 25) containing the nucleotide sequence
  • Figure 24 shows a consensus nucleotide sequence designated "DNA308430 from dna” (SEQ ID No: 28) derived from the alignment of a number of EST sequences.
  • Figure 25 shows a BLAST alignment of a portion of the PR0261 amino acid sequence derived from the DNA33473-seq min molecule (SEQ ID No: 29) with a portion of human CTGF (SEQ ID NO: 30).
  • Figure 26 shows a nucleotide sequence (SEQ ID No: 31) containing the nucleotide sequence (SEQ ID NO: 32) of a native sequence PR0246 cDNA (nucleotides 126-1295), wherein the nucleotide sequence (SEQ ID No: 31) is designated herein as "UNQ220" and/or "DNA35639".
  • the putative transmembrane domain of the protein is encoded by nucleotides beginning at nucleotide 855 in the figure.
  • Figure 27 shows the amino acid sequence (PRO 246; SEQ ID NO: 33) derived from nucleotides 126-1295 of the nucleotide sequence shown in Figure 26.
  • Figure 28 shows a consensus nucleotide sequence designated "DNA30955" (SEQ ID NO: 34) derived from the alignment of various EST sequences.
  • Figure 29 shows a BLAST sequence alignment of a portion of the PR0246 amino acid sequence derived from the DNA35639 molecule (“DNA35639”) (SEQ ID NO: 35) with a portion of the human cell surface protein HCAR ("HSU907161 ", SEQ ID NO: 36).
  • Figure 30 shows the nucleotide sequence of a native-sequence EBAF-2 cDNA (SEQ ID NO: 40), its complementary sequence (SEQ ID NO: 38), the nucleotide sequence encoding residues 1-366 of the deduced amino acid sequence of a native-sequence EBAF-2 (SEQ ID NO: 39), and the derived amino acid sequence of a native-sequence EBAF-2 (SEQ ID NO: 40).
  • Figure 31 shows the virtual DNA 28722 (SEQ ID NO: 41) from which the oligonucleotide PCR primers were generated to screen various libraries to isolate a full-length sequence.
  • Figure 32 describes the BLAST score, match, and percent homology alignment between the protein human EBAF-2 (SEQ ID NO: 40), encoded by DNA33461 (SEQ ID NO: 37), and human EBAF (hereafter called EBAF- 1 ) (SEQ ID NO: 42).
  • Figure 33 is a family tree showing the relationship between the EBAF-2 protein and other members of the TGF- ⁇ superfamily.
  • Figure 34 is an in situ image showing the expression of DNA49435 over the gallbladder epithelium in adult tissues.
  • Figure 35 is an in situ image showing moderate expression of DNA32286 in placental stromal cells in membranous tissues.
  • Figure 36 is an in situ image showing moderate expression of DNA32286 in thyroid.
  • Figure 37 is an in situ image showing low level expression of DNA32286 in cortical neurons.
  • Figure 38 is an in situ image showing an intense signal associated with the expression of DNA33223 in arterial and venous vessels in the fetus. In arteries, the signal appeared to be confined to smooth- muscle/pericytic cells.
  • Figure 39 is an in situ image showing strong expression of DNA33223 in cells within placental trophoblastic villi.
  • Figure 40 in an in situ image showing strong expression of DNA35639 in fetal vascular endothelium.
  • Figure 41 shows the consensus sequence DNA28744 used in the identification of cDNA (DNA32286) encoding PR0214 (an EGF-like homologue).
  • Figure 42 shows the results of framework and epicenter mapping of PRO230 .
  • Figure 43 shows the results of epicenter and framework mapping of PR0240. Detailed Description of the Invention . I. Definitions
  • gene amplification and “gene duplication” are used interchangeably and refer to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line.
  • the duplicated region (a stretch of amplified DNA) is often referred to as "amplicon.”
  • amplicon a stretch of amplified DNA
  • the amount of the messenger RNA (mRNA) produced i.e. the level of gene expression, also increases in the proportion of the number of copies made of the particular gene expressed.
  • Tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
  • cancers include breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.
  • Treatment is an intervention performed with the intention of preventing the development or altering the pathology of a disorder. Accordingly, “treatment” refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
  • a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g. radiation and/or chemotherapy.
  • the "pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, etc.
  • “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal is human.
  • “Carriers” as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution.
  • physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt- forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and PLURONICSTM.
  • Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.
  • cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
  • the term is intended to include radioactive isotopes (e.g. ⁇ l31 jl25 ⁇ 90 ⁇ R e 186 ⁇ chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.
  • chemotherapeutic agent is a chemical compound useful in the treatment of cancer.
  • chemotherapeutic agents include adriamycin, doxorubicin, epirubicin, 5-fluorouracil, cytosine arabinoside ("Ara-C”), cyclophosphamide, thiotepa, busulfan, cytoxin, taxoids, e.g.
  • paclitaxel Texol, Bristol- Myers Squibb Oncology, Princeton, NJ
  • doxetaxel Tetraxotere, Rh ⁇ ne-Poulenc Rorer, Antony, Rnace
  • toxotere methotrexate
  • cisplatin melphalan
  • vinblastine bleomycin
  • etoposide ifosfamide
  • mitomycin C mitoxantrone
  • vincristine vinorelbine
  • carboplatin teniposide, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycins, esperamicins (see U.S. Pat. No. 4,675,187), melphalan and other related nitrogen mustards.
  • hormonal agents that act to regulate or inhibit hormone action on tumors such as tamoxifen and onapristone.
  • a “growth inhibitory agent” when used herein refers to a compound or composition which inhibits growth of a cell, especially cancer cell overexpressing any of the genes identified herein, either in vitro or in vivo.
  • the growth inhibitory agent is one which significantly reduces the percentage of cells overexpressing such genes in S phase.
  • growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G 1 arrest and M-phase arrest.
  • Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin.
  • DNA alkylating agents such as tamoxifen, prednisone. dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled “Cell cycle regulation, oncogens, and antineoplastic drugs” by Murakami et al. (WB Saunders: Philadelphia, 1995), especially p. 13.
  • Doxorubicin is an athracycline antibiotic.
  • the full chemical name of doxorubicin is (8S-cis)- 10-[(3-amino-2,3,6-trideoxy- ⁇ -L-lyxo-hexapyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,l l-trihydroxy-8- (hydroxyacetyl)- 1 -methoxy-5, 12-naphthacenedione.
  • cytokine is a generic term for proteins released by one cell population which act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones.
  • cytokines include growth hormone such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor- ⁇ and - ⁇ ; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- ⁇ ; platelet-growth factor; transforming growth factors (TGFs) such as TGF-oc and TGF- ⁇ ; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; inter
  • a "PRO 187" polypeptide (“UNQ161”, an FGF-8 homologue); a "PR0533” polypeptide (“UNQ334", an FGF homologue); a “PR0214” polypeptide ("UNQ188", an EGF-like homologue); a “PRO240” polypeptide (“UNQ214”; a serrate homologue); a “PR0211 " polypeptide (“UNQ185”, an EGF-like homologue); a "PRO230” polypeptide ("UNQ204”, a polypeptide having homology to tubulointerstitial nephritis antigen (TTN)); a "PR0261 " polypeptide (“UNQ228”, a polypeptide having homology to the connective tissue growth factor (CTGF)); a "PR0246” polypeptide (“UNQ220”, a polypeptide having homology to the cell surface protein HCAR); and an "EBAF-2" polypeptide (a TGF- ⁇ superfamily member) are used to
  • Such native sequence PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can be isolated from nature or, along with the respective fragments, can be produced by recombinant and/or synthetic means.
  • the term specifically encompasses naturally-occurring truncated or secreted forms (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • the native sequence PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 is a full-length native presequence or a mature form of a PRO 187 polypeptide shown in Figure 2 (SEQ ID NO: 2); PR0533 polypeptide shown in Figure 6 (SEQ ID NO: 6); PR0214 polypeptide shown in Figure 10 (SEQ ID NO: 10); PRO240 polypeptide shown in Figure 12 (SEQ ID NO: 12); PR0211 polypeptide shown in Figure 17 (SEQ ID NO: 19); PRO230 polypeptide shown in Figure 18 (SEQ ID NO: 20); PR0261 polypeptide shown in Figure 23 (SEQ ID NO: 27); PR0246 polypeptide shown in Figure 27 (SEQ ID NO: 33), and EBAF-2 polypeptide shown in Figure 30 (SEQ ID NO: 40), respectively.
  • Fragments of the respective native polypeptides herein include, but are not limited, to polypeptide variants from which the native N-terminal signal sequence has been fully or partially deleted or replaced by another sequence, and extracellular domains of the respective native sequences, regardless whether such truncated (secreted) forms occur in nature.
  • PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2- encoding nucleic acid.
  • An isolated PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding nucleic acid molecule as it exists in natural cells.
  • an isolated nucleic acid molecule encoding a PR0187, PR0533, PR0214, PRO240, PR0211 , PR0230, PR0261 , PR0246, or EB AF-2 polypeptide includes nucleic acid molecules contained in cells that ordinarily express PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF- 2, where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
  • control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
  • control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
  • Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
  • Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al, Current Protocols in Molecular Biology. Wiley Interscience Publishers, (1995).
  • “Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin 0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 °C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 ⁇ g/ml), 0.1% SDS, and 10% dextran sul
  • Modely stringent conditions may be identified as described by Sambrook et al, Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent than those described above.
  • moderately stringent conditions is overnight incubation at 37 °C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C.
  • the skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
  • epitope tagged when used herein refers to a chimeric polypeptide comprising a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide fused to a "tag polypeptide".
  • the tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused.
  • the tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes.
  • Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).
  • Active or “activity” in the context of molecules identified based upon the PROl 87, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptides refers to polypeptides (e.g. antibodies) or organic or inorganic small molecules, peptides, etc. which retain the biological and/or immunological activities/properties of a native or naturally-occurring PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2.
  • Bioactivity in the context of an antibody or another molecule that can be identified by the screening assays disclosed herein (e.g. an organic or inorganic small molecule, peptide, etc.) is used to refer to the ability of such molecules to bind or complex with the polypeptides encoded by the amplified genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins.
  • a preferred biological activity is growth inhibition of a target tumor cell.
  • Another preferred biological activity is cytotoxic activity resulting in the death of the target tumor cell.
  • immunological property means immunological cross-reactivity with at least one epitope of a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • Immunological cross-reactivity means that the candidate polypeptide is capable of competitively inhibiting the qualitative biological activity of a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide having this activity with polyclonal antisera raised against the known active PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • antisera are prepared in conventional fashion by injecting goats or rabbits, for example, subcutaneously with the known active analogue in complete Freund's adjuvant, followed by booster intraperitoneal or subcutaneous injection in incomplete Freunds.
  • the immunological cross-reactivity preferably is "specific", which means that the binding affinity of the immunologically cross-reactive molecule (e.g. antibody) identified, to the corresponding PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide is significantly higher (preferably at least about 2-times, more preferably at least about 4-times, even more preferably at least about 8-times, most preferably at least about 8-times higher) than the binding affinity of that molecule to any other known native polypeptide.
  • the immunologically cross-reactive molecule e.g. antibody
  • antagonist is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide disclosed herein.
  • agonist is used in the broadest sense and includes any molecule that mimics a biological activity of a native PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide disclosed herein.
  • Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native polypeptides, peptides, small organic molecules, etc.
  • a "small molecule” is defined herein to have a molecular weight below about 500 daltons.
  • Antibodies are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.
  • antibody is used in the broadest sense and specifically covers, without limitation, intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
  • “Native antibodies” and “native immunoglobulins” are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V ⁇ ) followed by a number of constant domains.
  • V ⁇ variable domain
  • Each light chain has a variable domain at one end (V j ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.
  • variable refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR).
  • CDRs complementarity-determining regions
  • FR framework
  • the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a ⁇ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
  • the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al, NIHPubl. No.91-3242, Vol. I, pages 647- 669 (1991)).
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
  • Antibody fragments comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
  • antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (Zapata et al. , Protein Eng. 8(101:1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab” fragments, each with a single antigen-binding site, and a residual "Fc” fragment, whose name reflects its ability to crystallize readily.
  • Pepsin treatment yields an F(ab')2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
  • Fv is the minimum antibody fragment which contains a complete antigen-recognition and
  • variable domain This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non- covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V ⁇ -V ⁇ dimer.
  • the six CDRs confer antigen-binding specificity to the antibody.
  • a single variable domain or half of an Fv comprising only three CDRs specific for an antigen
  • the Fab fragment also contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain.
  • Fab fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • the "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (K) and lambda ( ⁇ ), based on the amino acid sequences of their constant domains.
  • immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgA, and IgA2.
  • the heavy-chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , e, ⁇ , and ⁇ , respectively.
  • the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al, Nature.256:495 [1975], or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567).
  • the “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al, Nature. 352:624-628 [1991] and Marks et al, J. Mol. Biol. 222:581-597 (1991), for example.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et al, Proc. Natl. Acad. Sci. USA. 8L6851-6855 [1984]).
  • chimeric antibodies immunoglobulins in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat or rabbit having the desired specificity, affinity, and capacity.
  • Fv FR residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • the humanized antibody includes a PRIMATIZEDTMantibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.
  • Single-chain Fv or “sFv” antibody fragments comprise the VJJ and V ⁇ domains of antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the VJJ and V ⁇ domains which enables the sFv to form the desired structure for antigen binding.
  • diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VJJ) connected to a light-chain variable domain (N L ) in the same polypeptide chain (V H - V j J).
  • VJJ heavy-chain variable domain
  • N L light-chain variable domain
  • Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al. Proc. Natl. Acad. Sci. USA. 90:6444-6448 (1993).
  • an “isolated” antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
  • the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • label when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody.
  • the label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
  • solid phase is meant a non-aqueous matrix to which the antibody of the present invention can adhere.
  • solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones.
  • the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.
  • a “liposome” is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as an PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261 , PR0246, or EBAF-2 polypeptide or an antibody thereto and, optionally, a chemotherapeutic agent) to a mammal.
  • a drug such as an PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261 , PR0246, or EBAF-2 polypeptide or an antibody thereto and, optionally, a chemotherapeutic agent
  • the components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
  • immunoadhesin designates antibody-like molecules which combine the binding specificity of a heterologous protein (an “adhesin”) with the effector functions of immunoglobulin constant domains.
  • the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is “heterologous"), and an immunoglobulin constant domain sequence.
  • the adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand.
  • the immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM. II. Compositions and Methods of the Invention
  • PRQ187 PRQ533.
  • PRQ246. and EBAF-2 polypeptides The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PR0187 (UNQ161), PR0533 (UNQ334), PR0214 (UNQ188), PRO240 (UNQ214), PR0211 (UNQ185), PRO230 (UNQ204), PR0261 (UNQ228), PR0246 (UNQ220), or EBAF-2.
  • PR0187 N-derived nucleotide sequences encoding polypeptides referred to in the present application as PR0187 (UNQ161), PR0533 (UNQ334), PR0214 (UNQ188), PRO240 (UNQ214), PR0211 (UNQ185), PRO230 (UNQ204), PR0261 (UNQ228), PR0246 (UNQ220), or EBAF-2.
  • proteins produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed.
  • the proteins encoded by nucleic acid referred to as "DNA27864", “DNA49435", “DNA32286”, “DNA34387”, -'DNA32292", “DNA33223”, “DNA33473”, “DNA35639”, and “DNA33461”, as well as all further native homologues and variants included in the foregoing definition of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide, will be referred to as "PR0187”, “PR0533”, “PR0214”, “PRO240”, “PR0211”, “PRO230”, “PR0261”, “PR0246”, or “EBAF-2” polypeptide, regardless of their origin or mode of expression.
  • the description below relates primarily to production of PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, and EBAF-2 polypeptides by culturing cells transformed or transfected with a vector containing PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptides.
  • the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide sequence, or portions thereof may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis. W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc. 85.-2149-2154 (1963)].
  • In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions.
  • PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2.
  • PRQ211. PRO230. PRQ261. PRQ246. or EBAF-2 polypeptide DNA encoding PRO 187, PR0533, PR0214, PRO240, PR0211 , PRO230, PR0261 , PR0246, or EBAF-2 may be obtained from a cDNA library prepared from tissue believed to possess the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 mRNA and to express it at a detectable level.
  • human PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EB AF-2 DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples.
  • the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding gene may also be obtained from a genomic library or by oligonucleotide synthesis.
  • Probes such as antibodies to the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide, or oligonucleotides of at least about 20-80 bases
  • Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989).
  • Methods of labeling are well known in the art, and include the use of radiolabels like P-labeled ATP, biotinylation or enzyme labeling.
  • Hybridization conditions including moderate stringency and high stringency, are provided in Sambrook et al., supra.
  • Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as ALIGN, DNAstar, and INHERIT which employ various algorithms to measure homology.
  • Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA. ii. Selection and Transformation of Host Cells
  • Host cells are transfected or transformed with expression or cloning vectors described herein for PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • the culture conditions such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach. M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.
  • transfection is performed using standard techniques appropriate to such cells.
  • the calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers.
  • Infection with Agrobacterium tumefaciens is used for transformation of certain plant cells, as described by Shaw et al., Gene. 22:315 (1983) and WO 89/05859 published 29 June 1989.
  • the calcium phosphate precipitation method of Graham and van der Eb, Virology.
  • Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells.
  • Suitable prokaryotes include but are not limited to eubacteria, such as Gram- negative or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli.
  • Various E. coli strains are publicly available, such as E. coli K12 strain MM294 (ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635).
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding vectors.
  • Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism.
  • Suitable host cells for the expression of glycosylated PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 are derived from multicellular organisms.
  • invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells.
  • useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV 1 line transformed by S V40 (COS-7, ATCC CRL 1651 ); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J.
  • the nucleic acid (e.g., cDNA or genomic DNA) encoding PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression.
  • a replicable vector for cloning (amplification of the DNA) or for expression.
  • Various vectors are publicly available.
  • the vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage.
  • the appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
  • Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.
  • the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • a heterologous polypeptide which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • the signal sequence may be a component of the vector, or it may be a part of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding DNA that is inserted into the vector.
  • the signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat- stable enterotoxin II leaders.
  • the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces ⁇ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990.
  • mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
  • Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 ⁇ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.
  • Selection genes will typically contain a selection gene, also termed a selectable marker.
  • Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding nucleic acid, such as DHFR or thymidine kinase.
  • An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al, Proc. Natl. Acad. Sci. USA. 77:4216 (1980).
  • a suitable selection gene for use in yeast is the trp ⁇ gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature.
  • the trp ⁇ gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics. 85:12 (1977)].
  • Expression and cloning vectors usually contain a promoter operably linked to the PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding nucleic acid sequence to direct mRNA synthesis.
  • Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the ⁇ -lactamase and lactose promoter systems [Chang et al., Nature. 275:615 (1978); Goeddel et al., Nature.
  • Suitable promoting sequences for use with yeast hosts include the promoters for 3-phos ⁇ hoglycerate kinase [Hitzeman et al., J. Biol. Chem..255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzv e Reg.. 7:149 (1968); Holland, Biochemistry.
  • enolase such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose- 6-phosphate isomerase, 3 -phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
  • enolase such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose- 6-phosphate isomerase, 3 -phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
  • yeast promoters which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
  • PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
  • viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2),
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription.
  • Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, ⁇ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus.
  • Examples include the SV40 enhancer on the late side of the replication origin (bp 100- 270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • the enhancer may be spliced into the vector at a position 5' or 3' to the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 coding sequence, but is preferably located at a site 5' from the promoter.
  • Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2.
  • Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA. 77:5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein.
  • antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.
  • the antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
  • Gene expression alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product.
  • Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal.
  • the antibodies may be prepared against a native sequence PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261 , PR0246, or EB AF-2 polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 DNA and encoding a specific antibody epitope.
  • PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptides may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents. It may be desired to purify PR0187, PR0533, PR0214, PRO240, PR0211, PRO230,
  • PR0261, PR0246, or EBAF-2 from recombinant cell proteins or pol peptides.
  • the following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptides.
  • PRQ211. PRO230. PRQ261. PRQ246. or EBAF-2 Polypeptides in Tumor Tissues and Cell Lines The present invention is based on the identification and characterization of genes which are amplified in certain cancer cells.
  • the genome of prokaryotic and eukaryotic organisms is subjected to two seemingly conflicting requirements.
  • One is the preservation and propagation of DNA as the genetic information in its original form, to guarantee stable inheritance through multiple generations.
  • cells or organisms must be able to adapt to lasting environmental changes.
  • the adaptive mechanisms can include qualitative or quantitative modifications of the genetic material.
  • Qualitative modifications include DNA mutations, in which coding sequences are altered resulting in a structurally and/or functionally different protein.
  • Gene amplification is a quantitative modification, whereby the actual number of complete coding sequence, i.e. a gene, increases, leading to an increased number of available templates for transcription, an increased number of translatable transcripts, and, ultimately, to an increased abundance of the protein encoded by the amplified gene.
  • MTX cytotoxic drug methotrexate
  • DHFR dihydrofolate reductase
  • Gene amplification is most commonly encountered in the development of resistance to cytotoxic drugs (antibiotics for bacteria and chemotherapeutic agents for eukaryotic cells) and neoplastic transformation. Transformation of a eukaryotic cell as a spontaneous event or due to a viral or chemical/environmental insult is typically associated with changes in the genetic material of that cell.
  • One of the most common genetic changes observed in human malignancies are mutations of the p53 protein. p53 controls the transition of cells from the stationary (Gl) to the replicative (S) phase and prevents this transition in the presence of DNA damage.
  • Gl stationary
  • S replicative
  • one of the main consequences of disabling p53 mutations is the accumulation and propagation of DNA damage, i.e. genetic changes.
  • Common types of genetic changes in neoplastic cells are, in addition to point mutations, amplifications and gross, structural alterations, such as translocations.
  • the amplification of DNA sequences may indicate specific functional requirement as illustrated in the DHFR experimental system. Therefore, the amplification of certain oncogenes in malignancies points toward a causative role of these genes in the process of malignant transformation and maintenance of the transformed phenotype.
  • This hypothesis has gained support in recent studies.
  • the bcl-2 protein was found to be amplified in certain types of non-Hodgkin's lymphoma. This protein inhibits apoptosis and leads to the progressive accumulation of neoplastic cells.
  • Members of the gene family of growth factor receptors have been found to be amplified in various types of cancers suggesting that overexpression of these receptors may make neoplastic cells less susceptible to limiting amounts of available growth factor.
  • Examples include the amplification of the androgen receptor in recurrent prostate cancer during androgen deprivation therapy and the amplification of the growth factor receptor homologue ERB2 in breast cancer.
  • genes involved in intracellular signaling and control of cell cycle progression can undergo amplification during malignant transformation. This is illustrated by the amplification of the bcl-l and ras genes in various epithelial and lymphoid neoplasms.
  • CGH comparative genomic hybridization
  • Tumor and normal DNA are hybridized simultaneously onto metaphases of normal cells and the entire genome can be screened by image analysis for DNA sequences that are present in the tumor at an increased frequency.
  • image analysis for DNA sequences that are present in the tumor at an increased frequency.
  • this type of analysis has revealed a large number of recurring amplicons (a stretch of amplified DNA) in a variety of human neoplasms.
  • CGH is more sensitive than classical cytogenetic analysis in identifying amplified stretches of DNA, it does not allow a rapid identification and isolation of coding sequences within the amplicon by standard molecular genetic techniques.
  • PCR polymerase chain reaction
  • PCR-based assays are most suitable for the final identification of coding sequences, i.e. genes in amplified regions. According to the present invention, such genes have been identified by quantitative PCR (S.
  • Human lung carcinoma cell lines include A549 (SRCC768), Calu-1 (SRCC769), Calu-6 (SRCC770), H157 (SRCC771), H441 (SRCC772), H460 (SRCC773), SKMES-1 (SRCC774) and SW900 (SRCC775), all available from ATCC.
  • Primary human lung tumor cells usually derive from adenocarcinomas, squamous cell carcinomas, large cell carcinomas, non-small cell carcinomas, small cell carcinomas, and broncho alveolar carcinomas, and include, for example, SRCC724 (squamous cell carcinoma abbreviated as "SqCCa”), SRCC725 (non-small cell carcinoma, abbreviated as "NSCCa”), SRCC726 (adenocarcinoma.
  • SqCCa squamous cell carcinoma abbreviated as "SqCCa”
  • SRCC725 non-small cell carcinoma
  • SRCC726 adenocarcinoma.
  • SRCC727 (adenocarcinoma), SRCC728 (squamous cell carcinoma), SRCC729 (adenocarcinoma), SRCC730 (adeno/squamous cell carcinoma), SRCC731 (adenocarcinoma), SRCC732 (squamous cell carcinoma), SRCC733 (adenocarcinoma), SRCC734 (adenocarcinoma), SRCC735 (broncho alveolar carcinoma, abbreviated as "BAC”), SRCC736 (squamous cell carcinoma), SRCC738 (squamous cell carcinoma), SRCC739 (squamous cell carcinoma), SRCC740 (squamous cell carcinoma), SRCC740 (lung cell carcinoma, abbreviated as "LCCa”).
  • Colon cancer cell lines include, for example, ATCC cell lines SW480 (adenocarcinoma, SRCC776), SW620 (lymph node metastasis of colon adenocarcinoma, SRCC777), COLO320 (adenocarcinoma, SRCC778), HT29 (adenocarcinoma, SRCC779), HM7 (carcinoma, SRCC780), CaWiDr (adenocarcinoma, srcc781), HCT116 (carcinoma, SRCC782), SKCOl (adenocarcinoma, SRCC783), SW403 (adenocarcinoma, SRCC784), LS174T (carcinoma, SRCC785), and HM7 (a high mucin producing variant of ATCC colon adenocarcinoma cell line LS 174T, obtained from Dr.
  • ATCC cell lines SW480 adenocarcinoma, SRCC
  • Primary colon tumors include colon adenoocarcinomas designated CT2 (SRCC742), CT3 (SRCC743), CT8 (SRCC744), CT10 (SRCC745), CT12 (SRCC746), CT14 (SRCC747), CT15 (SRCC748), CT17 (SRCC750), CTl (SRCC751), CT4 (SRCC752), CT5 (SRCC753), CT6 (SRCC754), CT7 (SRCC755), CT9 (SRCC756), CTl 1 (SRCC757), CTl 8 (SRCC758), and DcR3, BACrev, BACfwd, T160, and T159.
  • CT2 colon adenoocarcinomas designated CT2 (SRCC742), CT3 (SRCC743), CT8 (SRCC744), CT10 (SRCC745), CT12 (SRCC746), CT14 (SRCC747), CT15 (SRCC748), CT17 (SRCC750), CTl (SRCC751), CT4
  • Human breast carcinoma cell lines include, for example, HBL100 (SRCC759), MB435s (SRCC760), T47D (SRCC761), MB468(SRCC762), MB175 (SRCC763), MB361 (SRCC764), BT20 (SRCC765), MCF7 (SRCC766), SKBR3 (SRCC767).
  • results of the gene amplification assays herein can be verified by further studies, such as, by determining mRNA expression in various human tissues.
  • gene amplification and/or gene expression in various tissues may be measured by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, Proc.
  • Antibodies useful for immunohistochemical staining and or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261 , PR0246, or EB AF-2 polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PR0187, PR0533, PR0214, PRO240, PR0211, PRO230,
  • PR0261, PR0246, or EBAF-2 DNA and encoding a specific antibody epitope are provided hereinbelow. 4. Chromosome Mapping
  • the gene can be mapped to a particular chromosome, e.g. by radiation-hybrid analysis. The amplification level is then determined at the location identified, and at neighboring genomic region. Selective or preferential amplification at the genomic region to which to gene has been mapped is consistent with the possibility that the gene amplification observed promotes tumor growth or survival. Chromosome mapping includes both framework and epicenter mapping. For further details see e.g., Stewart et al, Genome Research 7, 422-433 (1997). 5. Antibody Binding Studies
  • the results of the gene amplification study can be further verified by antibody binding studies, in which the ability of anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibodies to inhibit the effect of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptides on tumor (cancer) cells is tested.
  • Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies, the preparation of which will be described hereinbelow.
  • Antibody binding studies may be carried out in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques, pp.147-158 (CRC Press, Inc., 1987).
  • ком ⁇ онентs rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody.
  • the amount of target protein (encoded by a gene amplified in a tumor cell) in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies.
  • the antibodies preferably are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.
  • Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected.
  • the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex.
  • the second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti- immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay).
  • sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.
  • the tumor sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.
  • Cell-Based Tumor Assays Cell-based assays and animal models for tumors (e.g. cancers) can be used to verify the findings of the gene amplification assay, and further understand the relationship between the genes identified herein and the development and pathogenesis of neoplastic cell growth.
  • the role of gene products identified herein in the development and pathology of tumor or cancer can be tested by using primary tumor cells or cells lines that have been identified to amplify the genes herein.
  • Such cells include, for example, the breast, colon and lung cancer cells and cell lines listed above.
  • cells of a cell type known to be involved in a particular tumor are transfected with the cDNAs herein, and the ability of these cDNAs to induce excessive growth is analyzed.
  • Suitable cells include, for example, stable tumor cells lines such as, the B104-1-1 cell line (stable NIH-3T3 cell line transfected with the neu protooncogene) and r s-transfected NIH-3T3 cells, which can be transfected with the desired gene, and monitored for tumorogenic growth.
  • transfected cell lines can then be used to test the ability of poly- or monoclonal antibodies or antibody compositions to inhibit tumorogenic cell growth by exerting cytostatic or cytotoxic activity on the growth of the transformed cells, or by mediating antibody-dependent cellular cytotoxicity (ADCC).
  • ADCC antibody-dependent cellular cytotoxicity
  • Cells transfected with the coding sequences of the genes identified herein can further be used to identify drug candidates for the treatment of cancer.
  • primary cultures derived from tumors in transgenic animals (as described below) can be used in the cell-based assays herein, although stable cell lines are preferred. Techniques to derive continuous cell lines from transgenic animals are well known in the art (see, e.g. Small et al. Mol. Cell. Biol. 5, 642-648 [1985]).
  • Animal Models A variety of well known animal models can be used to further understand the role of the genes identified herein in the development and pathogenesis of tumors, and to test the efficacy of candidate therapeutic agents, including antibodies, and other antagonists of the native polypeptides, including small molecule antagonists. The in vivo nature of such models makes them particularly predictive of responses in human patients.
  • Animal models of tumors and cancers e.g. breast cancer, colon cancer, prostate cancer, lung cancer, etc.
  • Non-recombinant animal models include, for example, rodent, e.g., murine models.
  • Such models can be generated by introducing tumor cells into syngeneic mice using standard techniques, e.g.
  • nude mice Probably the most often used animal species in oncological studies are immunodeficient mice and, in particular, nude mice.
  • the autosomal recessive nu gene has been introduced into a very large number of distinct congenic strains of nude mouse, including, for example, AS W, A He, AKR, B ALB/c, B 10.LP, C 17, C3H, C57BL, C57, CBA, DBA, DDD, I st, NC, NFR,
  • the cells introduced into such animals can be derived from known tumor/cancer cell lines, such as, any of the above-listed tumor cell lines, and, for example, the B104-1-1 cell line (stable NIH-3T3 cell line transfected with the neu protooncogene); r ⁇ s-transfected NIH-3T3 cells; Caco-2 (ATCC HTB-37); a moderately well-differentiated grade II human colon adenocarcinoma cell line, HT-29 (ATCC HTB-38), or from tumors and cancers.
  • Samples of tumor or cancer cells can be obtained from patients undergoing surgery, using standard conditions, involving freezing and storing in liquid nitrogen (Karmali et al, Br. J. Cancer 48, 689- 696 [1983]).
  • Tumor cells can be introduced into animals, such as nude mice, by a variety of procedures.
  • the subcutaneous (s.c.) space in mice is very suitable for tumor implantation.
  • Tumors can be transplanted s.c. as solid blocks, as needle biopsies by use of a trochar, or as cell suspensions.
  • tumor tissue fragments of suitable size are introduced into the s.c. space.
  • Cell suspensions are freshly prepared from primary tumors or stable tumor cell lines, and injected subcutaneously.
  • Tumor cells can also be injected as subdermal implants. In this location, the inoculum is deposited between the lower part of the dermal connective tissue and the s.c. tissue. Boven and Winograd (1991), supra.
  • Animal models of breast cancer can be generated, for example, by implanting rat neuroblastoma cells (from which the neu oncogen was initially isolated), or neu -transformed NIH-3T3 cells into nude mice, essentially as described by Drebin et al. PNAS USA 83, 9129-9133 (1986).
  • animal models of colon cancer can be generated by passaging colon cancer cells in animals, e.g. nude mice, leading to the appearance of tumors in these animals.
  • An orthotopic transplant model of human colon cancer in nude mice has been described, for example, by Wang etal, Cancer Research 54.4726- 4728 (1994) and Too et al, Cancer Research 55, 681-684 (1995). This model is based on the so-called “METAMOUSE” sold by AntiCancer, Inc. (San Diego, California).
  • Tumors that arise in animals can be removed and cultured in vitro. Cells from the in vitro cultures can then be passaged to animals. Such tumors can serve as targets for further testing or drug screening. Alternatively, the tumors resulting from the passage can be isolated and RNA from pre-passage cells and cells isolated after one or more rounds of passage analyzed for differential expression of genes of interest. Such passaging techniques can be performed with any known tumor or cancer cell lines.
  • Meth A, CMS4, CMS5, CMS21, and WEHI-164 are chemically induced fibrosarcomas of BALB/c female mice (DeLeo et al, J. Exp. Med. 146. 720 [1977]), which provide a highly controllable model system for studying the anti-tumor activities of various agents (Palladino et al, J. Immunol. 138.4023-4032 [1987]). Briefly, tumor cells are propagated in vitro in cell culture. Prior to injection into the animals, the cell lines are washed and suspended in buffer, at a cell density of about 10x10 to 10x10 cells/ml.
  • the animals are then infected subcutaneously with 10 to 100 ⁇ l of the cell suspension, allowing one to three weeks for a tumor to appear.
  • the Lewis lung (3LL) carcinoma of mice which is one of the most thoroughly studied experimental tumors, can be used as an investigational tumor model. Efficacy in this tumor model has been correlated with beneficial effects in the treatment of human patients diagnosed with small cell carcinoma of the lung (SCCL).
  • SCCL small cell carcinoma of the lung
  • This tumor can be introduced in normal mice upon injection of tumor fragments from an affected mouse or of cells maintained in culture (Zupi et al, Br. J. Cancer 41, suppl.4, 309 [1980]), and evidence indicates that tumors can be started from injection of even a single cell and that a v ery high proportion of infected tumor cells survive. For further information about this tumor model see Zacharski, Haemostasis 16, 300-320 [1986]).
  • One way of evaluating the efficacy of a test compound in an animal model is implanted tumor is to measure the size of the tumor before and after treatment.
  • the size of implanted tumors has been measured with a slide caliper in two or three dimensions.
  • the measure limited to two dimensions does not accurately reflect the size of the tumor, therefore, it is usually converted into the corresponding volume by using a mathematical formula.
  • the measurement of tumor size is very inaccurate.
  • the therapeutic effects of a drug candidate can be better described as treatment-induced growth delay and specific growth delay.
  • Another important variable in the description of tumor growth is the tumor volume doubling time.
  • Computer programs for the calculation and description of tumor growth are also available, such as the program reported by Rygaard and Spang-Thomsen, Proc. 6th Int.
  • Recombinant (transgenic) animal models can be engineered by introducing the coding portion of the genes identified herein into the genome of animals of interest, using standard techniques for producing transgenic animals.
  • Animals that can serve as a target for transgenic manipulation include, without limitation, mice, rats, rabbits, guinea pigs, sheep, goats, pigs, and non-human primates, e.g.
  • baboons, chimpanzees and monkeys Techniques known in the art to introduce a transgene into such animals include pronucleic microinjection (Hoppe and Wanger, U.S. Patent No. 4,873,191); retrovirus-mediated gene transfer into germ lines (e.g., Van der Putten et al, Proc. Natl. Acad. Sci. USA 82. 6148-615 [1985]); gene targeting in embryonic stem cells (Thompson et al, C ⁇ U ⁇ 6, 313-321 [ 1989]); electroporation of embryos (Lo, Mol. CeL. Biol.
  • transgenic animals include those that carry the transgene only in part of their cells ("mosaic animals").
  • the transgene can be integrated either as a single transgene, or in concatamers, e.g., head-to-head or head-to-tail tandems. Selective introduction of a transgene into a particular cell type is also possible by following, for example, the technique of Lasko et al, Proc. Natl. Acad. Sci. USA 89. 6232-636 (1992).
  • the expression of the transgene in transgenic animals can be monitored by standard techniques.
  • Southern blot analysis or PCR amplification can be used to verify the integration of the transgene.
  • the level of mRNA expression can then be analyzed using techniques such as in situ hybridization, Northern blot analysis, PCR, or immunocytochemistry.
  • the animals are further examined for signs of tumor or cancer development.
  • "knock out" animals can be constructed which have a defective or altered gene encoding a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide identified herein, as a result of homologous recombination between the endogenous gene encoding the polypeptide and altered genomic DNA encoding the same polypeptide introduced into an embryonic cell of the animal.
  • cDNA encoding a particular PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide can be used to clone genomic DNA encoding that polypeptide in accordance with established techniques.
  • a portion of the genomic DNA encoding a particular PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration.
  • flanking DNA typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, Cell. 5 .:503 (1987) for a description of homologous recombination vectors].
  • the vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., Cell. 69:915 (1992)].
  • the selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152].
  • a chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal.
  • Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA.
  • Knockout animals can be characterized for instance, by their ability to defend against certain pathological conditions and by their development of pathological conditions due to absence of the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • SCC feline oral squamous cell carcinoma
  • Feline oral SCC is a highly invasive, malignant tumor that is the most common oral malignancy of cats, accounting for over 60% of the oral tumors reported in this species. It rarely metastasizes to distant sites, although this low incidence of metastasis may merely be a reflection of the short survival times for cats with this tumor.
  • These tumors are usually not amenable to surgery, primarily because of the anatomy of the feline oral cavity. At present, there is no effective treatment for this tumor.
  • each cat Prior to entry into the study, each cat undergoes complete clinical examination, biopsy, and is scanned by computed tomography (CT). Cats diagnosed with sublingual oral squamous cell tumors are excluded from the study. The tongue can become paralyzed as a result of such tumor, and even if the treatment kills the tumor, the animals may not be able to feed themselves.
  • CT computed tomography
  • Each cat is treated repeatedly, over a longer period of time. Photographs of the tumors will be taken daily during the treatment period, and at each subsequent recheck.
  • CT scans and thoracic radiograms are evaluated every 8 weeks thereafter. The data are evaluated for differences in survival, response and toxicity as compared to control groups. Positive response may require evidence of tumor regression, preferably with improvement of quality of life and/or increased life span.
  • Screening assays for drug candidates are designed to identify compounds that bind or complex with the polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins.
  • Such screening assays will include assays amenable to high- throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.
  • Small molecules contemplated include synthetic organic or inorganic compounds, including peptides, preferably soluble peptides, (poly)peptide-immunoglobulin fusions, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments.
  • the assays can be performed in a variety of formats, including protein- protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.
  • All assays are common in that they call for contacting the drug candidate with a polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.
  • the interaction is binding and the complex formed can be isolated or detected in the reaction mixture.
  • the polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g. on a microtiter plate, by covalent or non-covalent attachments.
  • Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the polypeptide and drying.
  • an immobilized antibody e.g. a monoclonal antibody, specific for the polypeptide to be immobilized can be used to anchor it to a solid surface.
  • the assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g.
  • the coated surface containing the anchored component When the reaction is complete, the non-reacted components are removed, e.g. by washing, and complexes anchored on the solid surface are detected.
  • the detection of label immobilized on the surface indicates that complexing occurred.
  • complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex. If the candidate compound interacts with but does not bind to a particular PROl 87, PR0533,
  • PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide encoded by a gene identified herein its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions.
  • assays include traditional approaches, such as, cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns.
  • protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers [Fields and Song, Nature (Londonl 340. 245-246 (1989); Chien et al, Proc. Natl. Acad. Sci.
  • yeast GAL4 consist of two physically discrete modular domains, one acting as the DNA-binding domain, while the other one functioning as the transcription activation domain.
  • the yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain.
  • GALl-Z ⁇ cZ reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for ⁇ -galactosidase.
  • a complete kit (MATCHMAKER ) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.
  • compositions and Methods for the Treatment of Tumors include, without limitation, antibodies, small organic and inorganic molecules, peptides, phosphopeptides, antisense and ribozyme molecules, triple helix molecules, etc. that inhibit the expression and/or activity of the target gene product.
  • antisense RNA and RNA molecule act to directly block the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation.
  • antisense DNA oligodeoxyribonucleotides derived from the translation initiation site, e.g. between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.
  • Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
  • Ribozymes act by sequence-specific hybridization to the complementary target RNA. followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g. Rossi. Current Biology 4. 469-471 (1994), and PCT publication
  • Nucleic acid molecules in triple helix formation used to inhibit transcription should be single- stranded and composed of deoxynucleotides.
  • the base composition of these oligonucleotides is designed such that it promotes triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex.
  • Hoogsteen base pairing rules which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex.
  • polyclonal antibodies Some of the most promising drug candidates according to the present invention are antibodies and antibody fragments which may inhibit the production or the gene product of the amplified genes identified herein and/or reduce the activity of the gene products.
  • Polyclonal Antibodies Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections.
  • the immunizing agent may include the PROl 87, PR0533,
  • PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide or a fusion protein thereof may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized.
  • immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor.
  • adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryi Lipid A, synthetic trehalose dicorynomycolate).
  • the immunization protocol may be selected by one skilled in the art without undue experimentation. ii. Monoclonal Antibodies
  • the anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibodies may, alternatively, be monoclonal antibodies.
  • Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature. 256:495 (1975).
  • a hybridoma method a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
  • the lymphocytes may be immunized in vitro.
  • the immunizing agent will typically include the PR0187, PR0533, PR0214, PRO240,
  • PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide including fragments, or a fusion protein of such protein or a fragment thereof.
  • PBLs peripheral blood lymphocytes
  • spleen cells or lymph node cells are used if non-human mammalian sources are desired.
  • the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice. Academic Press, (1986) pp. 59-103].
  • Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed.
  • the hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT)
  • HGPRT or HPRT hypoxanthine guanine phosphoribosyl transferase
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.
  • Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection (ATCC), Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol. 33_:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications. Marcel Dekker, Inc., New York, (1987) pp. 51-63].
  • the culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2.
  • the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard. Anal. Biochem.. 107:220 (19801.
  • the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.
  • the monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • the monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567.
  • DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells of the invention serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., supra] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
  • non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
  • the antibodies may be monovalent antibodies.
  • Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain.
  • the heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking.
  • the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.
  • the anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibodies may further comprise humanized antibodies or human antibodies.
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • CDR complementary determining region
  • donor antibody non-human species
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature. 221:522-525 (1986); Riechmann et al., Nature.222:323-329 (1988); and Presta, Curr. Op. Struct. Biol.. 2:593-596 (1992)].
  • Fc immunoglobulin constant region
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain.
  • Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature.321:522-525 (1986); Riechmann et al., Nature.222:323-327 (1988); Verhoeyen et al., Science. 229:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues .are substituted by residues from analogous sites in rodent antibodies.
  • Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol.. 227:381 (1991); Marks et al., J. Mol. Biol.. 22 ⁇ :581 ( 1991 )] .
  • the techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, p. 77 (1985) and
  • human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806;
  • Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens.
  • one of the binding specificities is for the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.
  • bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature.205:537-539 [1983]). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture often different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J.. 10:3655-3659 (1991).
  • Antibody variable domains with the desired binding specificities can be fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI) containing the site necessary for light-chain binding present in at least one of the fusions.
  • CHI first heavy-chain constant region
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980. vi.
  • effector function engineering It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance the effectiveness of the antibody in treating cancer, for example.
  • cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al. , J. Exp jVJed. 176:1191-1195 (1992) and Shopes, B. J. Immunol.148:2918-2922 (1992).
  • Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research 52:2560-2565 (1993).
  • an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al, Anti- Cancer Drug Design 3:219-230 (1989). vii. Immunoconiugates
  • the invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g. an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
  • a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g. an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
  • Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes.
  • a variety of radionuclides are available for the production of radioconjugated antibodies. Examples include Bi, I, 131 In, 90 Y and 186 Re.
  • Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis- diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6- diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene).
  • SPDP N-succinimidyl-3-(
  • a ricin immunotoxin can be prepared as described in Vitetta et al. , Science 238: 1098 (1987).
  • Carbon- 14-labeled 1- isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See W094/11026.
  • the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g. avidin) which is conjugated to a cytotoxic agent (e.g. a radionucleotide).
  • a ligand e.g. avidin
  • cytotoxic agent e.g. a radionucleotide
  • the antibodies disclosed herein may also be formulated as immunoliposomes.
  • Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al, Proc. Natl. Acad. Sci. USA. 82:3688 (1985); Hwang et al, Proc. Natl Acad. Sci. USA. 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.
  • Particularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
  • Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al .. J. Biol. Chem. 257: 286-288 (1982) via a disulfide interchange reaction.
  • a chemotherapeutic agent such as Doxorubicin is optionally contained within the liposome. See Gabizon et al.., J. National Cancer Inst. 81(1911484 (1989).
  • Antibodies specifically binding the product of an amplified gene identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of tumors, including cancers, in the form of pharmaceutical compositions.
  • the protein encoded by the amplified gene is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred.
  • lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment which specifically binds to the binding domain of the target protein is preferred.
  • peptide molecules can be designed which retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology (see, e.g. Marasco et al, Proc. Natl. Acad. Sci. USA 90, 7889-7893 [1993]).
  • Therapeutic formulations of the antibody are prepared for storage by mixing the antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. [1980]), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine,
  • Non-antibody compounds identified by the screening assays of the present invention can be formulated in an analogous manner, using standard techniques well known in the art.
  • the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • the composition may comprise a cytotoxic agent, cytokine or growth inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • the active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin- microcapsules andpolyJmethylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
  • Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.
  • copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(- )-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • encapsulated antibodies When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions. 11. Methods of Treatment
  • the antibodies and other anti-tumor compounds of the present invention may be used to treat various conditions, including those characterized by overexpression and/or activation of the amplified genes identified herein.
  • exemplary conditions or disorders to be treated with such antibodies and other compounds including, but not limited to, small organic and inorganic molecules, peptides, antisense molecules, etc. include benign or malignant tumors (e.g.
  • the anti-tumor agents of the present invention are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous administration of the antibody is preferred.
  • chemotherapeutic agents may be administered to the patient. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service Ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992).
  • the chemotherapeutic agent may precede, or follow administration of the anti- tumor agent, e.g. antibody, or may be given simultaneously therewith.
  • the antibody may be combined with an anti-oestrogen compound such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812) in dosages known for such molecules.
  • the antibodies herein are co-administered with a growth inhibitory agent.
  • the growth inhibitory agent may be administered first, followed by an antibody of the present invention.
  • simultaneous administration or administration of the antibody of the present invention first is also contemplated. Suitable dosages for the growth inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth inhibitory agent and the antibody herein.
  • an anti-tumor agent e.g. an antibody herein
  • the appropriate dosage of an anti-tumor agent will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the agent is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the agent, and the discretion of the attending physician.
  • the agent is suitably administered to the patient at one time or over a series of treatments.
  • ⁇ g/kg to 15 mg/kg (e.g. 0.1-20mg/kg) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
  • a typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above.
  • the treatment is sustained until a desired suppression of disease symptoms occurs.
  • other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. 12.
  • an article of manufacture containing materials useful for the diagnosis or treatment of the disorders described above comprises a container and a label.
  • Suitable containers include, for example, bottles, vials, syringes, and test tubes.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is effective for diagnosing or treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • the active agent in the composition is usually an anti-tumor agent capable of interfering with the activity of a gene product identified herein, e.g. an antibody.
  • the label on, or associated with, the container indicates that the composition is used for diagnosing or treating the condition of choice.
  • the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. 13. Diagnosis and Prognosis of Tumors
  • antibodies directed against the proteins products of genes amplified in tumor cells can be used as tumor diagnostics or prognostics.
  • antibodies can be used to qualitatively or quantitatively detect the expression of proteins encoded by the amplified genes ("marker gene products").
  • the antibody preferably is equipped with a detectable, e.g. fluorescent label, and binding can be monitored by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. These techniques are particularly suitable, if the amplified gene encodes a cell surface protein, e.g. a growth factor.
  • binding assays are performed essentially as described in section 5 above.
  • In situ detection of antibody binding to the marker gene products can be performed, for example, by immunofluorescence or immunoelectron microscopy.
  • a histological specimen is removed from the patient, and a labeled antibody is applied to it, preferably by overlaying the antibody on a biological sample.
  • This procedure also allows for determining the distribution of the marker gene product in the tissue examined. It will be apparent for those skilled in the art that a wide variety of histological methods are readily available for in situ detection.
  • EST expressed sequence tag
  • DNA database (LIFESEQ , Incyte Pharmaceuticals, Palo Alto, CA) was searched and an EST (#843193) was identified which showed homology to fibroblast growth factor (FGF-8) also known as androgen-induced growth factor.
  • FGF-8 fibroblast growth factor
  • mRNA was isolated from human fetal lung tissue using reagents and protocols from Invitrogen, San Diego, CA (Fast Track 2).
  • the cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents. (E.g., Invitrogen, San Diego, CA, Life Technologies, Gaithersburg, MD).
  • the cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into the cloning vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System).
  • the double stranded cDNA was sized to greater than 1000 bp and the Sall/NotI linkered cDNA was cloned into XhoI/NotI cleaved vector.
  • pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an Sfil restriction enzyme site preceding the XhoI/NotI cDNA cloning sites.
  • a positive library was then used to isolate clones encoding the FGF-8 homologue gene using one of the above oligonucleotides and the following oligonucleotide probe:
  • the EST sequence accession number AF007268 a murine fibroblast growth factor (FGF- 15) was used to search various public EST databases (e.g., GenBank, Dayhoff, etc.). The search was performed using the computer program BLAST or BLAST2 [Altschul et al., Methods in Enzvmology.266:460-480 (1996); http://blast.wustl edu/blast/README.html] as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. The search resulted in a hit with GenBank EST AA220994, which has been identified as stratagene NT2 neuronal precursor 937230.
  • GenBank EST AA220994 which has been identified as stratagene NT2 neuronal precursor 937230.
  • oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence.
  • Forward and reverse PCR primers may range from 20 to 30 nucleotides (typically about 24), and are designed to give a PCR product of 100-1000 bp in length.
  • the probe sequences (notated as *.p) are typically 40-55 bp (typically about 50) in length.
  • DNA from the libraries was screened by PCR amplification, as per
  • DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PR0533 gene using the probe oligonucleotide and one of the PCR primers.
  • RNA for construction of the cDNA libraries was isolated from human fetal retina.
  • the cDNA libraries used to isolated the cDNA clones were constructed by standard methods using commercially available reagents (e.g., Invitrogen, San Diego, CA; Clontech.
  • the cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al., Science, 253:1278-1280 ( 1991 )) in the unique Xhol and NotI sites.
  • a suitable cloning vector such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al., Science, 253:1278-1280 ( 1991 )
  • a cDNA clone was sequenced in its entirety.
  • the full length nucleotide sequence of PR0533 is shown in Figure 5 (SEQ ID NO: 5).
  • Clone DNA49435 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 459-461 (Fig. 5; SEQ ID NO: 5).
  • the predicted polypeptide precursor is 216 amino acids long.
  • Clone DNA49435-1219 has been deposited with ATCC (November 21, 1997) and is assigned ATCC deposit no. 209480.
  • PR0533 shows amino acid sequence identity to fibroblast growth factor (FGF) (53%).
  • FGF15J ATCCGCCCAGATGGCTACAATGTGTA (SEQ ID NO: 58)
  • FGF15.p GCCTCCCGGTCTCCCTGAGCAGTGCCAAACAGCGGCAGTGTA (SEQ ID NO: 59)
  • FGF15.r CCAGTCCGGTGACAAGCCCAAA (SEQ ID NO: 60)
  • PR0533 (UNQ334) encoded by DNA49435 has been identified as a specific ligand for FGF receptor 3, exhibiting exclusive binding to this receptor. As mice deficient in FGF receptor 3 are known to have major defects in bone growth and are deaf, PR0533 is anticipated to play a role in cartilage and bone growth and may be useful to prevent and/or treat hearing loss.
  • ECD extracellular domain
  • the EST databases included public EST databases (e.g., GenBank), and a proprietary EST database (LIFESEQ , Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program
  • BLAST or BLAST2 [Altschul et al., Methods in Enzvmology. 266:460-480 (1996); http://blast.wustl/edu/blast/README.html] as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons resulting in a BLAST score of 70 (or in some cases, 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap” (Phil Green, University of Washington, Seattle, Washington; http://bozeman.mbt.washington. edu/phrap.docs/phrap.html).
  • a consensus DNA sequence encoding EGF-like homologue was assembled using phrap. This consensus DNA sequence is indicated as DNA28744 (SEQ ID NO: 61) in Fig.41.
  • oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full- length coding sequence.
  • Forward and reverse PCR primers may range from 20 to 30 nucleotides (typically about 24), and are designed to give a PCR product of 100-1000 bp in length.
  • the probe sequences (notated as *.p) are typically 40-55 bp (typically about 50) in length.
  • additional oligonucleotides are synthesized when the consensus sequence is greater than 1-1.5 kbp.
  • DNA from the libraries was screened by PCR amplification, as per Ausubel et al, supra, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest by the in vivo cloning procedure suing the probe oligonucleotide and one of the PCR primers.
  • the library used to isolate DNA32286 was human fetal lung.
  • DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the EGF-like homologue gene using the probe oligonucleotide and one of the PCR primers.
  • RNA for construction of the cDNA libraries was isolated from identify tissue type.
  • the cDNA libraries used to isolated the cDNA clones were constructed by standard methods using commercially available reagents (e.g., Invitrogen, San Diego, CA; Clontech, etc.)
  • the cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al., Science, 253:1278-1280 (1991)) in the unique Xhol and NotI sites.
  • a suitable cloning vector such as pRKB or pRKD; pRK5B is
  • a cDNA clone was sequenced in its entirety.
  • the full length nucleotide sequence of EGF-like homologue is shown in Figure 9 (SEQ ID NO: 9).
  • DNA32286 contains a single open reading frame with an apparent translational initiation site at nucleotide position 103 (Fig. 9; SEQ ID NO: 9).
  • the predicted polypeptide precursor is 420 amino acids long (Fig. 10, SEQ ID NO: 10).
  • EGF- like homologue DNA32286 shows amino acid sequence identity to HT protein and/or Fibulin (49% and 38%, respectively).
  • the extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known secreted proteins from the Swiss-Prot public protein database were used to search expressed sequence tag (EST) databases.
  • the EST databases included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ , Incyte Pharmaceuticals, Palo Alto, CA).
  • the search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzvmology 266:460- 480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequence. Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap” (Phil Green, University of Washington, Seattle, Washington).
  • oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PRO240.
  • a pair of PCR primers (forward and reverse) were synthesized: forward PCR primer 5'-TCAGCTCCAGACTCTGATACTGCC-3' (SEQ ID NO: 65) reverse PCR nrimer 5'-TGCCTTTCTAGGAGGCAGAGCTCC-3' (SEQ ID NO: 66) Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30873 sequence which had the following nucleotide sequence
  • hybridization probe 5'-GGACCCAGAAATGTGTCCTGAGAATGGATCTTGTGTACCTGATGGTCCAG-3' SEQ ID NO: 67.
  • RNA for construction of the cDNA libraries was isolated from human fetal liver tissue.
  • the cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA.
  • the cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al., Science. 252:1278-1280 (1991)) in the unique Xhol and NotI sites.
  • a suitable cloning vector such as pRKB or pRKD; pRK5B is a precursor of pR
  • the extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases.
  • the EST databases included public databases (e.g., Dayhoff, GenBank), and proprietary databases (e.g. LIFESEQ , Incyte Pharmaceuticals, Palo Alto, CA).
  • the search was performed using the computer program BLAST or BLAST2 (Altschul, SF and Gish (1996), Methods in Enzymology 266: 460-80 (1996); http://blast.wustl/edu/blast/README.html) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences.
  • a consensus DNA sequences encoding an EGF-like homologue was assembled using phrap.
  • the consensus DNA sequence (DNA28730) was extended by repeated cycles of blast and phrap as far as possible using the three sources of EST sequences listed above.
  • oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full- length coding sequence.
  • the pair of forward and reverse PCR primers may range from 20 to 30 nucleotides (typically 24), and are designed to give a PCR product of 100- 1000 bp in length.
  • the probe sequences (notated as *.p) are typically 40-55 bp (typically 50) in .length. In some cases additional oligonucleotides are synthesized when the consensus sequence is greater than 1-1.5 kbp.
  • DNA from the libraries was screened by PCR amplification, as per Ausubel et al, supra, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest by the in vivo cloning procedure using the probe oligonucleotide and one of the PCR primers. This library used to isolate DNA32292 fetal lung.
  • RNA for the construction of the cDNA libraries was isolated using standard isolation protocols, e.g., Ausubel et al, supra, from tissue or cell line sources or it was purchased from commercial sources (e.g., Clontech).
  • the cDNA libraries used to isolate the cDNA clones were constructed by standard methods (e.g., Ausubel et al.) using commercially available reagents (e.g., Invitrogen).
  • the cDNA was primed with oligo dT containing a Noti site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation in a suitable cloning vector (pRK5B or pRK5D) in the unique Xhol and NotI sites.
  • a suitable cloning vector pRK5B or pRK5D
  • a cDNA clone was sequenced in its entirety.
  • the entire nucleotide sequence (DNA32292) of an EGF-like homologue (PR0211 ) is shown in Figure 16 (SEQ ID NO: 18).
  • the predicted polypeptide is 353 amino acids in length, respectively, with a molecule weight of approximately 38.19kDa.
  • cDNA clone 32292-1131 has been deposited at ATCC (September 16, 1997) and assigned ATCC no. 209258.
  • oligonucleotide sequences used in the above procedure were the following:
  • oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full- length coding sequence for PRO230.
  • a pair of PCR primers (forward and reverse) were synthesized: forward PCR primer 5'-TTCGAGGCCTCTGAGAAGTGGCCC-3' (SEQ ID NO: 71) reverse PCR primer 5'-GGCGGTATCTCTCTGGCCTCCC-3' (SEQ ID NO: 72)
  • oligonucleotide hybridization probe was constructed from the consensus DNA30857 sequence which had the following nucleotide sequence
  • DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PRO230 gene using the probe oligonucleotide and one of the PCR primers.
  • RNA for construction of the cDNA libraries was isolated from human fetal lung tissue.
  • the cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA.
  • the cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al., Science. 252:1278-1280 (1991)) in the unique Xhol and NotI sites.
  • a suitable cloning vector such as pRKB or pRKD; pRK5B is a precursor of pR
  • the extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known secreted proteins from the Swiss-Prot public protein database were used to search expressed sequence tag (EST) databases.
  • the EST databases included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQTM, Incyte Pharmaceuticals, Palo Alto, CA).
  • the search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzvmology 266:460- 480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequence.
  • oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR0261.
  • Forward and reverse PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 bp in length.
  • the probe sequences are typically 40-55 bp in length.
  • additional oligonucleotides are synthesized when the consensus sequence is greater than about l-1.5kbp.
  • DNA from the libraries was screened by PCR amplification, as per Ausubel et al., Current Protocols in Molecular Biology, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest by the in vivo cloning procedure using the probe oligonucleotide and one of the primer pairs.
  • DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A positive library was then used to isolate clones encoding the PR0261 gene using the probe oligonucleotide and one of the PCR primers.
  • RNA for construction of the cDNA libraries was isolated from human fetal lung tissue.
  • the cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA.
  • the cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al., Science. 252:1278-1280 (1991)) in the unique Xhol and NotI sites.
  • a suitable cloning vector such as pRKB or pRKD; pRK5B is a precursor of pR
  • AAAGGTGCGTACCCAGCTGTGCC (SEQ ID NO: 74)
  • the extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known secreted proteins from the Swiss-Prot public protein database were used to search expressed sequence tag (EST) databases.
  • the EST databases included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQTM, Incyte Pharmaceuticals, Palo Alto, CA).
  • the search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzvmology 266:460- 480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequence. Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap” (Phil Green, University of Washington, Seattle, Washington).
  • DNA30955 Figure 28, SEQ ID NO: 34
  • oligonucleotides were synthesized to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for PR0246.
  • a pair of PCR primers were synthesized:
  • oligonucleotide hybridization probe was constructed from the consensus DNA30955 sequence which had the following nucleotide sequence
  • the cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the Sfil site; see, Holmes et al., Science. 252:1278-1280 (1991)) in the unique Xhol and NotI sites.
  • DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PR0246 [herein designated as UNQ220 (DNA35639)] (SEQ ID NO: 31) and the derived protein sequence for PR0246 (SEQ ID NO: 33).
  • the predicted polypeptide precursor is 390 amino acids long ( Figure 27).
  • Clone UNQ220 (DNA35639) has been deposited with ATCC on October 17, 1997 and is assigned ATCC deposit no.209396.
  • the extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the SWISS-PROT public database were used to search EST databases.
  • the EST databases included public EST databases (e.g., GenBank), and a proprietary EST database (LIFESEQ , Incyte Pharmaceuticals, Palo Alto, CA).
  • the search was performed using the computer program BLASTTM or BLAST2TM (Altschul et al, Methods in Enzvmology. 266:460-480 (1996); http://blast.wustl/edu/blast/README.html) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences.
  • a consensus DNA sequence encoding EBAF-2 (DNA 28722) was assembled using phrap, as shown in Figure 31 (SEQ ID NO: 41 ). Based on this consensus sequence, oligonucleotides were synthesized: 1 ) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence.
  • the forward and reverse PCR primers synthesized for this purpose were:
  • the probe synthesized for this purpose was:
  • mRNA for construction of the cDNA libraries was isolated from human fetal kidney tissue
  • PRK5B is a cloning vector that has an sp6 transcription initiation site and unique Xhol/Notl cDNA cloning sites. It is a precursor of pRK5D that does not contain the Sfil site (Holmes et al, Science.25 .: 1278-1280 (1991)).
  • the double-stranded cDNA was primed with oligo dT containing a NotI site, linked with blunt to Sail hemikinased adaptors, cleaved with NotI, sized to greater than 1000 bp appropriately by gel electrophoresis, and cloned in a defined orientation into the ATjo Wofl-cleaved pRK5B vector.
  • DNA from the libraries was screened by PCR amplification, as per Ausubel et al, supra, with the PCR primer pair identified above.
  • a positive library was then used to isolate clones containing the ebaf-1 gene using the probe oligonucleotide identified above and one of the PCR primers.
  • a cDNA clone was sequenced in its entirety. The entire nucleotide sequence of DNA33461
  • Clone DNA33461 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 68-70 (Fig. 30; SEQ ID NO: 37).
  • the predicted polypeptide precursor is 366 amino acids long.
  • the predicted signal sequence is amino acids 1-18 of Figure 30 (SEQ ID NO: 40).
  • Clone DNA33461 (designated DNA33461-1199) has been deposited with ATCC (October 15, 1997) and is assigned ATCC deposit no. 209367.
  • Figure 32 shows the BLAST score, match, and percent homology alignment between protein EBAF-2 (SEQ ID NO: 40), encoded by DNA33461 (SEQ ID NO: 37), and human EBAF- 1 (SEQ ID NO: 42). Based on this BLASTTM and FastATM sequence alignment analysis (using the ALIGNTM computer program) of the full-length sequence, EBAF-2 shows the most amino acid sequence identity to EBAF-1 (92%). The results also demonstrate a significant homology between human EBAF-2 and mouse LEFTY protein.
  • EXAMPLE 2 Gene Amplification This example shows that the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261 , PR0246, and EBAF-2-encoding genes are amplified in the genome of certain human lung, colon and/or breast cancers and/or cell lines. Amplification is associated with overexpression of the gene product, indicating that the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, and EBAF-2 proteins are useful targets for therapeutic intervention in certain cancers such as colon, lung, breast and other cancers.
  • Therapeutic agent may take the form of antagonists of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-encoding genes, for example, murine-human chimeric, humanized or human antibodies against a PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 (PR0317) polypeptide.
  • the starting material for the screen was genomic DNA isolated from a variety cancers.
  • the DNA is quantitated precisely, e.g. fluorometrically.
  • DNA was isolated from the cells of ten normal healthy individuals which was pooled and used as assay controls for the gene copy in healthy individuals (not shown).
  • the 5' nuclease assay for example, TaqManTM
  • real-time quantitative PCR for example, ABI Prizm 7700 Sequence Detection SystemTM (Perkin Elmer, Applied Biosystems Division, Foster City, CA)
  • the results were used to determine whether the DNA encoding PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246 or PR0317 is over-represented in any of the primary lung or colon cancers or cancer cell lines or breast cancer cell lines that were screened.
  • the primary lung cancers were obtained from individuals with tumors of the type and stage as indicated in Table 1. An explanation of the abbreviations used for the designation of the primary tumors listed in Table 1 and the primary tumors and cell lines referred to throughout this example has been given hereinbefore.
  • the results of the Taqman are reported in delta ( ⁇ ) CT units.
  • One unit corresponds 1 PCR cycle or approximately a 2-fold amplification relative to normal, two units corresponds to 4-fold, 3 units to 8-fold amplification and so on. Quantitation was obtained using primers and a Taqman fluorescent prove derived from the PR0187-, PR0533-, PR0214-, PRO240-, PR0211-, PRO230-, PR0261-, PR0246- or PR0317- encoding gene. Regions of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246 or PR0317 which are most likely to contain unique nucleic acid sequences and which are least likely to have spliced out introns are preferred for the primer and probe derivation, e.g.
  • PRQ214 (DNA322861 DNA32286.3utr-5 5'-GGGCCATCACAGCTCCCT-3' (SEQ ID NO: 89)
  • DNA32286.3utr-probe 5'-TGCCAGCTGCA TGCTGCCAGTT-3' SEQ ID NO: 91
  • PRO240 (DNA343871 DNA34387.3utr-5 5'-GTCAGGGAGCTCTGCTTCCTAG-3' (SEQ ID NO: 92) DNA34387.3utr-3
  • PRQ261 DNA334731 DNA33473.3utr-5 5'-TCTAGCCCACTCCCTGCCT-3' (SEQ ID NO: 104) DNA33473.3utr-3 5'-GAAGTCGGAGAAAGCTCGC-3' (SEQ ID NO: 105) DNA33473.3utr-probe 5'-CACACACAGCCTATATCAAACATGCACACG-3' (SEQ ID NO: 106)
  • PRQ246 DNA356391 DNA35639.3utr-5 5'-GGCAGAGACTTCCAGTCACTGA-3' (SEQ ID NO: 107) DNA35639.3utr-3
  • the 5' nuclease assay reaction is a fluorescent PCR-based technique which makes use of the 5' exonuclease activity of Taq DNA polymerase enzyme to monitor amplification in real time.
  • Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction.
  • a third oligonucleotide, or probe is designed to detect nucleotide sequence located between the two PCR primers.
  • the probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe.
  • the TAQ DNA polymerase enzyme cleaves the probe in a template-dependent manner.
  • the resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore.
  • One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.
  • the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI Prism 7700TM Sequence Detection.
  • the system consists of a thermocycler, laser, charge-coupled device (CCD) camera and computer.
  • the system amplifies samples in a 96-well format on a thermocycler.
  • laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD.
  • the system includes software for running the instrument and for analyzing the data.
  • Ct 5' Nuclease assay data are initially expressed as Ct, or the threshold cycle. This is defined as the cycle at which the reporter signal accumulates above the background level of fluorescence.
  • the ⁇ Ct values are used as quantitative measurement of the relative number of starting copies of a particular target sequence in a nucleic acid sample when comparing cancer DNA results to normal human DNA results.
  • Table 1 describes the stage, T stage and N stage of various primary tumors which were used to screen the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246 and PR0317 compounds of the invention.
  • Table 1 Primary Lung and Colon Tumor Profiles
  • DNA was prepared from cultured cell lines, primary tumors, normal human blood. The isolation was performed using purification kit, buffer set and protease and all from Quiagen, according to the manufacturer's instructions and the description below.
  • Cell culture lysis Cells were washed and trypsinized at a concentration of 7.5 x 10 per tip and pelleted by centrifuging at 1000 ⁇ m for 5 minutes at 4°C, followed by washing again with 1/2 volume of PBS recentrifugation. The pellets were washed a third time, the suspended cells collected and washed 2x with PBS. The cells were then suspended into 10 mL PBS. Buffer Cl was equilibrated at 4°C.
  • Quiagen protease #19155 was diluted into 6.25 ml cold ddH 2 0 to a final concentration of 20 mg/ml and equilibrated at 4°C. 10 mL of G2 Buffer was prepared by diluting Quiagen RNAse A stock (100 mg/ml) to a final concentration of 200 ⁇ g/ml.
  • Buffer Cl (10 mL, 4°C) and ddH20 (40 mL, 4°C ) were then added to the 10 mL of cell suspension, mixed by inverting and incubated on ice for 10 minutes.
  • the cell nuclei were pelleted by centrifuging in a Beckman swinging bucket rotor at 2500 ⁇ m at 4°C for 15 minutes. The supernatant was discarded and the nuclei were suspended with a vortex into 2 mL Buffer Cl (at 4°C) and 6 mL dcl ⁇ O, followed by a second 4°C centrifugation at 2500 ⁇ m for 15 minutes.
  • the nuclei were then resuspended into the residual buffer using 200 ⁇ l per tip.
  • Tumor samples were weighed and placed into 50 ml conical tubes and held on ice. Processing was limited to no more than 250 mg tissue per preparation (1 tip/preparation).
  • the protease solution was freshly prepared by diluting into 6.25 ml cold dd ⁇ O to a final concentration of 20 mg/ml and stored at 4°C.
  • G2 buffer (20 ml) was prepared by diluting DNAse A to a final concentration of 200 mg/ml (from 100 mg/ml stock).
  • the tumor tissue was homogenated in 19 ml G2 buffer for 60 seconds using the large tip of the polytron in a laminar- flow TC hood to order to avoid inhalation of aerosols, and held at room temperature.
  • the polytron was cleaned by spinning at 2 x 30 seconds each in 2L dd ⁇ O, followed by G2 buffer (50 ml). If tissue was still present on the generator tip, the apparatus was disassembled and cleaned. Quiagen protease (prepared as indicated above, 1.0 ml) was added, followed by vortexing and incubation at 50°C for 3 hours. The incubation and centrifugation was repeated until the lysates were clear (e.g., incubating additional 30-60 minutes, pelleting at 3000 x g for 10 min., 4°C).
  • RNAse A was prepared by diluting RNAse A to a final concentration of 200 ⁇ g/ml from 100 mg/ml stock.
  • the blood (10 ml) was placed into a 50 ml conical tube and
  • Quiagen protease was added (200 ⁇ l) and incubated at 50 °C for 60 minutes. The incubation and centrifugation was repeated until the lysates were clear (e.g., incubating additional 30-60 minutes, pelleting at 3000 x g for 10 min., 4°C).
  • Genomic DNA was equilibrated (1 sample per maxi tip preparation) with 10 ml QBT buffer.
  • QF elution buffer was equilibrated at 50°C.
  • the samples were vortexed for 30 seconds, then loaded onto equilibrated tips and drained by gravity. The tips were washed with 2 x 15 ml QC buffer.
  • the DNA was eluted into 30 ml silanized, autoclaved 30 ml Corex tubes with 15 ml QF buffer (50 C C). Isopropanol (10.5 ml) was added to each sample, the tubes covered with parafin and mixed by repeated inversion until the DNA precipitated.
  • Samples were pelleted by centrifugation in the SS-34 rotor at 15,000 ⁇ m for 10 minutes at 4°C. The pellet location was marked, the supernatant discarded, and 10 ml 70% ethanol (4°C) was added. Samples were pelleted again by centrifugation on the SS-34 rotor at 10,000 ⁇ m for 10 minutes at 4°C. The pellet location was marked and the supernatant discarded. The tubes were then placed on their side in a drying rack and dried 10 minutes at 37°C, taking care not to overdry the samples.
  • the pellets were dissolved into 1.0 ml TE (pH 8.5) and placed at 50°C for 1-2 hours. Samples were held overnight at 4°C as dissolution continued. The DNA solution was then transferred to 1.5 ml tubes with a 26 gauge needle on a tuberculin syringe. The transfer was repeated 5x in order to shear the DNA. Samples were then placed at 50°C for 1-2 hours.
  • the DNA levels in each tube were quantified by standard A260, A280 spectrophotometry on a 1:20 dilution (5 ⁇ l DNA + 95 ⁇ l ddH 2 0) using the 0.1 ml quartz cuvetts in the Beckman DU640 spectrophotometer. A260/A280 ratios were in the range of 1.8-1.9. Each DNA samples was then diluted further to approximately 200 ng/ml in TE (pH 8.5). If the original material was highly concentrated (about 700 ng/ ⁇ l), the material was placed at 50 °C for several hours until resuspended.
  • Fluorometric DNA quantitation was then performed on the diluted material (20-600 ng/ml) using the manufacturer's guidelines as modified below. This was accomplished by allowing a Hoeffer DyNA Quant 200 fluorometer to warm-up for about 15 minutes.
  • the Hoechst dye working solution (#H33258, 10 ⁇ l, prepared within 12 hours of use) was diluted into 100 ml 1 x TNE buffer.
  • a 2 ml cuvette was filled with the fluorometer solution, placed into the machine, and the machine was zeroed.
  • pGEM 3Zf(+) (2 ⁇ l, lot #360851026) was added to 2 ml of fluorometer solution and calibrated at 200 units.
  • the fluorometricly determined concentration was then used to dilute each sample to 10 ng/ ⁇ l in dd ⁇ O. This was done simultaneously on all template samples for a single TaqMan plate assay, and with enough material to run 500-1000 assays.
  • the samples were tested in triplicate with Taqman primers and probe both B-actin and GAPDH on a single plate with normal human DNA and no-template controls.
  • the diluted samples were used provided that the CT value of normal human DNA subtracted from test DNA was +/-
  • PRO230 (DNA33223) was also reexamined with both framework and epicenter mapping. Selected tumors from the above initial screen were reexamined with both framework and epicenter mapping.
  • Figure 42 and Table 3 indicate the chromosomal mapping of both the framework and epicenter markers that were used in the present example. The framework markers are located approximately every 20 megabases and were used to control aneuploidy.
  • Table 5 describes the epicenter markers that were employed in association with PRO230 (DNA33223). These markers are located in close proximity to DNA33223 and are used to assess the amplification status of the region of chromosome 1 in which DNA33223 is located. The distance between individual markers is measured in centirays, which is a radiation breakage unit approximately equal to a 1% chance of a breakage between two markers. One cR is very roughly equivalent to 20 kilobases.
  • the marker SHGC-35321 is the marker found to be the closest to the location on chromosome 1 where DNA33223 most closely maps.
  • Table 6 indicates the ⁇ Ct values for results of epicenter mapping relative to DNA33223, indicating the relative amplification in the region more immediate to the actual location of DNA33223 along chromosome 1.
  • PRO240 was also reexamined with epicenter mapping.
  • Table 7 describes the epicenter markers that were employed in association with PRO240 (DNA34387). These markers are located in close proximity to DNA34387 and are used to assess the amplification status of the region of chromosome 2 in which DNA34387 is located. The distance between individual markers is measured in centirays, which is a radiation breakage unit approximately equal to a 1% chance of a breakage between two markers. One cR is very roughly equivalent to 20 kilobases.
  • the marker SHGC-14626 is the marker along chromosome 2 which most closely maps to DNA34387; however, the Taqman i M primers and probes for SHGC-1426 failed in our assay, due to technical difficulties related to PCR.
  • DNA34387 was also found to be contained with a BAC (Bacterial Artificial Chromosome).
  • the full BAC was about 100 Kb.
  • the 5' and 3' ends were sequenced and used to generated the BAC primers indicated in Table 8. This confirms the validity of our original epicenter mapping results.
  • Table 8 indicates the DCt values for results of epicenter mapping relative to DNA34387, indicating the relative amplification in the immediate chromosomal region along Chromosome 2.
  • the ⁇ Ct values for DNA27864 (PRO 187) in a variety of lung tumors are reported in Table 2.
  • a ⁇ Ct value of > 1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • Table 2 indicates that significant amplification of DNA 27864 occurred in primary lung tumors LT12, LT13, LT15, and LT19.
  • the average ⁇ Ct values were 2.80, 2.86, 3.84 and 4.02. This represents approximately a 7.0, 7.3, 14.3 and 16.2 fold increase in gene copy relative to normal tissue.
  • antagonists e.g., antibodies directed against the protein encoded by DNA27864 (PR0187) would be expected to be useful in cancer therapy.
  • the ⁇ Ct values for DNA49435 (PR0533) in a variety of lung tumors are reported in Table 2.
  • a ⁇ Ct value of >1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • Table 2 indicates that amplification of DNA49435 occurred in primary lung tumors LTla, LT7, LT11, LT16, LT17 and LT19.
  • the ⁇ Ct values in these tumors were 1.02, 1.04, 1.09, 1.66, 1.32 and 1.67. This represents approximately a 2.0, 2.1, 2.1, 3.2, 2.5 and 3.2, respectively, fold increase in gene copy relative to normal tissue.
  • PRQ214 Because amplification of DNA49435 (PR0533) occurs in various tumors, it is likely associated with tumor formation or growth. As a result, antagonists (e.g., antibodies) directed against the protein encoded by DNA49435 (PR0533) would be expected to be useful in cancer therapy.
  • ⁇ Ct values for DNA32286 (PR0214) in a variety of lung and colon tumors are reported in Table 2.
  • a ⁇ Ct value of > 1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • Table 2 indicates that significant amplification of DNA32286 occurred in: (1) primary lung tumors LT3, LT11, LT12, LT13, LT15, LT17, LT19; and (2) primary colon tumors CT2, CT3, CT8, CT10, CT12, CT14, CT15, CT16, CT17, CTl, CT4, CT5, CT6 and CTl 1.
  • the ⁇ Ct and average ⁇ Ct values for the lung tumors were the following: 1.57, 1.74, 1.44, 1.84, 1.68, 1.90, 2.04, respectively; while the those for the primary colon tumors were: 2.49, 2.06, 1.48, 1.84, 1.81, 2.48, 1.63, 1.95, 2.04, 1.22, 1.36, 1.56, 1.33 and 2.05, respectively.
  • this represents approximately a 3.0, 3.3, 2.7, 3.6, 3.2, 3.7 and 4.1, respectively, fold increase in gene copy relative to normal tissue.
  • Table 2 A ⁇ Ct value of > 1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • Table 2 indicates that significant amplification of DNA34387 occurred in: (1) primary lung tumors LTla, LT3, LT6, LT10, LT11, LT12, LT13, LT15, LT16, LT17 and LT19; and (2) primary colon tumors CT2, CT3, CT8, CT10, CT12, CT14, CT15, CT16, CT17, CTl, CT4, CT5, CT6, CT7 and CTl 1.
  • the ⁇ Ct and average ⁇ Ct values for the primary lung tumors were the following: 1.36, 1.22, 1.12,
  • Additional epicenter mapping amplfication reported in Table 10 indicate that significant amplification of DNA34387 occured in primary lung tumors LTla, LT3, LT6, LT7, LT9, LT10, LT11, LT12, LT13, LT15, LT16, LT17, LT19 and LT21, which report ⁇ Ct's of 1.63, 1.97, 1.26, 1.06, 1.58, 1.41, 2.25, 3.11, 2.85, 3.78, 1.33, 2.20, 3.93 and 1.10, respectively. This represents approximately a 3.1, 3.9, 2.4, 2.1, 3.0, 2.6, 4.8, 8.6, 7.2, 13.7, 2.5, 4.6, 15.2 and 2.1, respectively, amplification in gene copy relative to normal tissue.
  • DNA34387 is very close to the BAC marker 208K21Forl, as the maker is amplification in the same pattern of tumors as DNA34387, and the degree of amplification is similar.
  • DNA34387 is the gene that is the cause for the amplification of the particular region on Chromosome 2. Because amplification of DNA34387 (PRO240) occurs in various tumors, it is likely to play a significant role in tumor formation or growth. As a result, antagonists (e.g., antibodies) directed against the protein encoded by DNA34387 (PRO240) would be expected to be useful in cancer therapy.
  • DNA34387 (PRO240) Because amplification of DNA34387 (PRO240) occurs in various tumors, it is likely associated with tumor formation or growth. As a result, antagonists (e.g., antibodies) directed against the protein encoded by DNA34387 (PRO240) would be expected to be useful in cancer therapy.
  • PRQ211 PRQ211 :
  • the ⁇ Ct values for DNA32292 (PR0211) in a variety of primary lung and colon tumors as well as lung tumor cell lines are reported in Table 2.
  • a ⁇ Ct value of > 1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • Table 2 indicates that significant amplification of DNA32292 in: (1) primary lung tumors LTla, LT3, LT4, LT9, LT10, LTl 1, LT12, LT13, LT15, LT16, LT17, LT19, LT21; (2) primary colon tumors CTl, CT4, CT5, CT6, CT11; and (3) lung tumor cell line SW900.
  • the ⁇ Ct and average ⁇ Ct values for the primary lung tumors were the following: 1.18, 1.97, 1.17, 1.42, 1.96, 1.97, 1.39, 2.07, 2.30, 1.06, 2.08, 2.49 and 1.12, respectively; while those for the primary colon tumors were: 1.27, 1.33, 1.76, 1.01 and 2.01; and the lung tumor cell line SW900 gave a ⁇ Ct value of 1.86.
  • this represents approximately a 2.3, 3.9, 2.2, 2.7, 3.9, 3.9. 2.6, 4.2, 4.9, 2.1, 4.2, 5.6 and 2.2, respectively, fold increase in gene copy relative to normal tissue.
  • DNA32292 is present in approximately 3.6 fold above normal levels. Because amplification of DNA32292 (PR0211) occurs in various tumors, it is likely associated with tumor formation or growth. As a result, antagonists (e.g, antibodies) directed against the protein encoded by DNA32292 (PR0211) would be expected to be useful in cancer therapy.
  • the ⁇ Ct values for DNA33223 (PRO230) in a variety of lung and colon tumors are shown in Table 2.
  • PRO230 were subjected to further framework and epicenter analysis.
  • a ⁇ Ct value of > 1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • the framework markers analysis reports the relative amplification of particular regions of chromosome 1 in the indicated tumors, while the epicenter markers analysis gives a more precise reading of the relative amplification in the region immediately in the vicinity of the gene of interest.
  • DNA33223 shows amplification in lung tumors LTla, LT3, LT6, LT9, LTIO, LT12, LT13, LT15 and LT19.
  • DNA33223 (PRO230) also shows amplification in colon tumors CT3, CT10, CT12, CT16, CT17, CTl, CT4, CT5, CT7 and CTl 1.
  • the ⁇ Ct values for DNA33473 (PR0261) in a variety of primary lung and colon tumors as well as lung tumor cell lines are reported in Table 2.
  • a ⁇ Ct value of > 1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • Table 2 indicates that significant amplification of DNA33474 in: (1) primary lung tumors LTla, LT10, LT12, LT15, LT17 and LT19; (2) primary colon tumors CT2, CT3, CT14, CT5; (3) colon tumor cell lines SW480, SW620, HT29, WiDr, HCT116, SKCOl, SW403, LS174T and (4) breast tumor cell lines HBL100, MB435s, BT20 and SKBR3.
  • the ⁇ Ct and average ⁇ Ct values for the primary lung tumors were the following: 1.08, 1.16, 1.17, 1.64, 1.50 and 1.47, respectively; those for the primary colon tumors were 1.16, 2.14, 1.03 and 1.07, respectively; those for the colon tumor cell lines 1.67, 1.54, 1.73, 1.24, 1.32, 1.35, 1.65, and 1.48, respectively; and those for the breast tumor cell lines were 1.40, 1.43, 1.66 and 1.73, respectively.
  • ⁇ Ct values for DNA35639 (PR0246) in a variety of primary lung tumors and lung tumor cell lines are reported in Table 2.
  • a ⁇ Ct value of > 1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • Table 2 indicates that significant amplification of DNA35639 in primary lung tumors LT3, LT10, LTl 1, LT12, LT13, LT15, LT17, LT19 and LT21.
  • the ⁇ Lt and average ⁇ Ct values for the primary lung tumors were the following: 1.06, 1.07, 2.42, 2.00, 1.65, 1.83, 2.18, 1.79 and 1.05, which represents a 2.1, 2.1, 5.3, 4.0, 3.1, 3.6, 4.5, 3.5 and 2.1, respectively, fold increase in gene copy relative to normal tissue.
  • ⁇ Ct values for DNA33461 (PR0317) in a variety of primary lung tumors and lung tumor cell lines are reported in Table 2.
  • a ⁇ Ct value of > 1 was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy.
  • Table 2 indicates significant amplification of DNA33461 in primary lung tumors LTla, LT3, LT4, LT6, LT7, LT9, LT10, LTl 1, LT12, LT13, LT15, LT16, LT17 and
  • the ⁇ Ct and average ⁇ Ct values for the primary lung tumors were the following: 1.29, 1.86, 1.18, 1.93, 1.52, 1.04, 2.57, 2.26, 2.14, 2.07, 2.41, 1.31, 2.16 and 2.27, which represents a 2.4, 3.6, 2.3, 3.8, 2.9, 2.1, 5.9, 4.8, 4.4, 4.2, 5.3, 2.5, 4.5 and 4.8, respectively, fold increase in gene copy relative to normal tissue
  • DNA33461 (PR0317) Because amplification of DNA33461 (PR0317) occurs in various tumors, it is likely associated with tumor formation or growth. As a result, antagonists (e.g., antibodies) directed against the protein encoded by DNA33461 (PR0317) would be expected to be useful in cancer therapy.
  • In situ hybridization is a powerful and versatile technique for the detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for example, to identify sites of gene expression, analyze the tissue distribution of transcription, identify and localize viral infection, follow changes in specific mRNA synthesis and aid in chromosome mapping. In situ hybridization was performed following an optimized version of the protocol by Lu and
  • P-Riboprobe synthesis 6.0 ⁇ l (125 mCi) of 33 P-UTP (Amersham BF 1002, SA ⁇ 2000 Ci/mmol) were speed vac dried. To each tube containing dried JJ P-UTP, the following ingredients were added: 2.0 ⁇ l 5x transcription buffer l.O ⁇ l DTT (lOO mM)
  • the probe was run on a TBE/urea gel. 1-3 ⁇ l of the probe or 5 ⁇ l of RNA Mrk 111 were added to 3 ⁇ l of loading buffer. After heating on a 95° C heat block for three minutes, the gel was immediately placed on ice. The wells of gel were flushed, the sample loaded, and run at 180-250 volts for 45 minutes. The gel was wrapped in saran wrap and exposed to XAR film with an intensifying screen in -70 °C freezer one hour to overnight.
  • Hybridization 1.0 x 10" cpm probe and 1.0 ⁇ l tRNA (50 mg/ml stock) per slide were heated at 95 °C for 3 minutes. The slides were cooled on ice, and 48 ⁇ l hybridization buffer were added per slide. After vortexing, 50 ⁇ l J P mix were added to 50 ⁇ l prehybridization on slide. The slides were incubated overnight at 55°C.
  • Oligo A-251G 46mer GGA TTC TAA TAC GAC TCA CTA TAG GGC GGA TCC TGG CCG GCC TCG GAA
  • Oligo B-138U 47mer GGA TTC TAA TAC GAC TCA CTA TAG GGC CCC TCC TGC CTT CCC TGT CC (SEQ ID NO: 45)
  • Oligo A- 134R 48mer CTA TGA AAT TAA CCC TCA CTA AAG GGA GTG GTG GCC GCG ATT ATC
  • TGC (SEQ ID NO: 46) In fetal tissues, low level expression was observed throughout the mesenchyme. Moderate expression was seen in placental stromal cells in membraneous tissues (Figure 35), and in thyroid (Figure 36). Low level expression was seen in cortical neurons ( Figure 37). DNA 34387 (Jagged/EGF homologuel
  • Oligo B-231 W 48mer GGA TTC TAA TAC GAC TCA CTA TAG GGC CCG AGA TAT GCA CCC AAT
  • Oligo DNA33223-pl GGA TTC TAA TAC GAC TCA CTA TAG GGC GGC GAT GTC CAC TGG GGC TAC (SEQ ID NO: 49)
  • Oligo DNA33223-p2 CTA TGA AAT TAA CCC TCA CTA AAG GGA CGA GGA AGA TGG GCG GAT GGT (SEQ ID NO: 50) Tissue sections showed an intense signal associated with arterial and venous vessels in the fetus.
  • vascular expression similar to the foregoing results, was observed in fetal blocks. Expression was seen on vascular smooth muscle, rather than endothelium. Expression was also seen in smooth muscle of the developing oesophagus, hence this molecule is not vascular specific. Expression was examined in 4 lung and 4 breast carcinomas. Substantial expression was seen in vascular smooth muscle of at least 3 out of 4 lung cancers and 2 out of 4 breast cancers. In addition, in one breast carcinoma (IF97-06551 3E), expression was observed in peritumoral stromal cells of uncertain histogenesis (possibly myofibroblasts). No endothelial cell expression was observed in this study. DNA33473 (CTGF homologuel Oligo D- 170R 45mer: GGA TTC TAA TAC GAC TCA CTA TAG GGC GCG AGG ACG GCG
  • Oligo D-170V 48mer CTA TGA AAT TAA CCC TCA CTA AAG GGA AGA GTC GCG GCC
  • Oligo B-258M 48mer GGA TTC TAA TAC GAC TCA CTA TAG GGC TTG CTG CGG TTT TTG TTC CTG (SEQ ID NO: 53)
  • Oligo B-258N 48mer CTA TGA AAT TAA CCC TCA CTA AAG GGA GCT GCC GAT CCC
  • PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide as a hybridization probe.
  • DNA comprising the coding sequence of full-length or mature PR0187, PR0533, PR0214,
  • PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 (as shown in Figure 2, SEQ ID NO:2; Figure 6,
  • SEQ ID NO: 6 is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2) in human tissue cDNA libraries or human tissue genomic libraries.
  • homologous DNAs such as those encoding naturally-occurring variants of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2
  • Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions.
  • Hybridization of radiolabeled PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1 x SSC and 0.1% SDS at 42°C.
  • PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can then be identified using standard techniques known in the art.
  • This example illustrates preparation of an unglycosylated form of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 by recombinant expression in E. coli.
  • the DNA sequence encoding PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 (SEQ ID NOs: 1; 8; 12; 14; 16; 25; 29; 35; and 40, respectively) is initially amplified using selected PCR primers.
  • the primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector.
  • restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector.
  • An example of a suitable vector is pBR322 (derived from E. coli; see Bolivar et al., Gene. 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance.
  • the vector is digested with restriction enzyme and dephosphorylated.
  • the PCR amplified sequences are then ligated into the vector.
  • the vector will preferably include sequences which encode for an antibiotic resistance gene, a tip promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PROl 87, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 coding region, lambda transcriptional terminator, and an argU gene.
  • the ligation mixture is then used to transform a selected E. coli strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.
  • Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics.
  • the overnight culture may subsequently be used to inoculate a larger scale culture.
  • the cells are then grown to a desired optical density, during which the expression promoter is turned on.
  • the cells After culturing the cells for several more hours, the cells can be harvested by centrifugation.
  • the cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.
  • PROl 87 (UNQ161) and EBAF-2 (UNQ278) were expressed in E. coli in apoly-His tagged form, using the following procedure.
  • the DNA encoding PROl 87 or EBAF-2 was initially amplified using selected PCR primers.
  • the primers contained restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase.
  • the PCR- amplified, poly-His tagged sequences were then ligated into an expression vector, which was used to transform an E. coli host based on strain 52 (W3110 fuhA(tonA) Ion galE ⁇ oHts(htpRts) clpP(laclq). Transformants were first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 was reached.
  • Cultures were then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH 4 ) 2 S0 4 , 0.71 g sodium citrate-2H20, 1.07 g KC1, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgS0 4 ) and grown for approximately 20-30 hours at 30°C with shaking. Samples were removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets were frozen until purification and refolding.
  • CRAP media prepared by mixing 3.57 g (NH 4 ) 2 S0 4 , 0.71 g sodium citrate-2H20, 1.07 g KC1, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH
  • E. coli paste from 0.5 to 1 L fermentations (6-10 g pellets) was resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer.
  • Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1 M and 0.02 M, respectively, and the solution was stirred overnight at 4°C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization.
  • the solution was centrifuged at 40,000 ⁇ m in a Beckman Ultracentifuge for 30 min.
  • the supernatant was diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. Depending the clarified extract was loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column was washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein was eluted with buffer containing 250 mM imidazole. Fractions containing the desired protein were pooled and stored at 4°C. Protein concentration was estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.
  • the proteins were refolded by diluting sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes were chosen so that the final protein concentration was between 50 to 100 micrograms/ml. The refolding solution was stirred gently at 4°C for 12-36 hours. The refolding reaction was quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the solution was filtered through a 0.22 micron filter and acetonitrile was added to 2-10% final concentration.
  • refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA. Refolding volumes were chosen so that the final
  • the refolded protein was chromatographed on a Poros Rl/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance were analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein were pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.
  • This example illustrates preparation of a potentially glycosylated form of PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 by recombinant expression in mammalian cells.
  • the vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector.
  • the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF- 2 DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 DNA using ligation methods such as described in Sambrook et al., supra.
  • the resulting vector is called pRK5-PR0187, pRK5-PR0533, pRK5- PR0214, pRK5-PRO240, pRK5-PR0211, pRK5-PRO230, pRK5-PR0261, pRK5-PR0246, or pRK5-EBAF-2.
  • the selected host cells may be 293 cells. Human 293 cells (ATCC CCL
  • 1573 are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics.
  • medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics.
  • About 10 ⁇ g pRK5-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 DNA is mixed with about 1 ⁇ g DNA encoding the VA RNA gene [Thimmappaya et al, CeU, 21:543 (1982)] and dissolved in 500 ⁇ l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M CaCl 2 .
  • the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200 ⁇ Ci/ml 5 S-cysteine and 200 ⁇ Ci/ml 35 S-methionine.
  • the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel.
  • the processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 polypeptide.
  • the cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.
  • PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 DNA may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al., Proc. Natl. Acad. Sci..12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700 ⁇ g pRK5- PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS.
  • the DNA-dextran precipitate is incubated on the cell pellet for four hours.
  • the cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5 ⁇ g/ml bovine insulin and 0.1 ⁇ g/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris.
  • the sample containing expressed PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.
  • PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can be expressed in CHO cells.
  • the pRK5- PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 vector can be transfected into CHO cells using known reagents such as CaP0 4 or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as J S-methionine.
  • the culture medium may be replaced with serum free medium.
  • the cultures are incubated for about 6 days, and then the conditioned medium is harvested.
  • the medium containing the expressed PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can then be concentrated and purified by any selected method.
  • Epitope-tagged PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 may also be expressed in host CHO cells.
  • the PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 may be subcloned out of the pRK5 vector.
  • the subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-His tag into a Baculovirus expression vector.
  • the poly-His tagged PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones.
  • the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression.
  • the culture medium containing the expressed poly-His tagged PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can then be concentrated and purified by any selected method, such as by Ni -chelate affinity chromatography.
  • PR0214 (UNQ188); PRO240 (UNQ214); PR0211 (UNQ185); PRO230 (UNQ204); and PR0261 (UNQ228) were expressed in CHO cells by both a transient and a stable expression procedure.
  • PR0246 (UNQ220) was transiently expressed in CHO cells.
  • the proteins were expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins were fused to an IgGl constant region sequence containing the hinge, CH2 and CH2 domains and or is a poly-His tagged form.
  • IgG construct immunoadhesin
  • CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's.
  • the vector used expression in CHO cells is as described in Lucas et al, Nucl. Acids Res. 24: 9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR).
  • DHFR expression permits selection for stable maintenance of the plasmid following transfection.
  • the ampules containing the plasmid DNA were thawed by placement into water bath and mixed by vortexing. The contents were pipetted into a centrifuge tube containing 10 mLs of media and centrifiiged at 1000 ⁇ m for 5 minutes. The supernatant was aspirated and the cells were resuspended in 10 mL of selective media (0.2 ⁇ m filtered PS20 with 5% 0.2 ⁇ m diafiltered fetal bovine serum). The cells were then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells were transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C.
  • selective media 0.2 ⁇ m filtered PS20 with 5% 0.2 ⁇ m diafiltered fetal bovine serum
  • a 250 mL, 500 mL and 2000 mL spinners were seeded with 3 x 10 cells/mL.
  • the cell media was exchanged with fresh media by centrifugation and resuspension in production medium.
  • any suitable CHO media may be employed, a production medium described in US Patent No. 5,122,469, issued June 16, 1992 was actually used.
  • 3L production spinner is seeded at 1.2 x 10 cells/mL. On day 0, the cell number pH were determined. On day 1 , the spinner was sampled and sparging with filtered air was commenced.
  • the spinner was sampled, the temperature shifted to 33 °C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion). Throughout the production, pH was adjusted as necessary to keep at around 7.2. After 10 days, or until viability dropped below 70%, the cell culture was harvested by centrifugtion and filtering through a 0.22 ⁇ m filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.
  • 10% antifoam e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion.
  • the proteins were purified using a Ni-NTA column (Qiagen). Before purification, imidazole was added to the conditioned media to a concentration of 5 mM. The conditioned media was pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 03 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml min. at 4°C. After loading, the column was washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole.
  • the highly purified protein was subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.
  • Immunoadhesin (Fc containing) constructs of were purified from the conditioned media as follows.
  • the conditioned medium was pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column was washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5.
  • the eluted protein was immediately neutralized by collecting 1 ml fractions into tubes containing 275 ⁇ L of 1 M Tris buffer, pH 9.
  • the highly purified protein was subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity was assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.
  • PR0187 (UNQ161); PR0533 (UNQ334); PR0214 (UNQ188): PRO240 (UNQ214); PR0211 (UNQ 185); PRO230 (UNQ204); PR0261 (UNQ228); PR0246 (UNQ220), and EBAF-2 (UNQ278) were also produced by transient expression in COS cells. EXAMPLE 7 Expression of PRQ187. PRQ533. PRQ214. PRO240. PRQ211. PRO230. PRQ261. PRQ246. and EBAF-2 in Yeast The following method describes recombinant expression of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 in yeast.
  • yeast expression vectors are constructed for intracellular production or secretion of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 from the ADH2/GAPDH promoter.
  • DNA encoding PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBaAF-2 and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2.
  • DNA encoding PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2.
  • yeast cells such as yeast strain AB110
  • yeast cells can then be transformed with the expression plasmids described above and cultured in selected fermentation media.
  • the transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.
  • EBAF-2 can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters.
  • PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 may further be purified using selected column chromatography resins.
  • the following method describes recombinant expression in Baculovirus-infected insect cells.
  • PR0246, or EBAF-2 is fused upstream of an epitope tag contained within a baculovirus expression vector.
  • epitope tags include poly-His tags and immunoglobulin tags (like Fc regions of IgG).
  • a variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen).
  • PRO230, PR0261, PR0246, or EBAF-2 [such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular] is amplified by PCR with primers complementary to the 5' and 3' regions.
  • the 5' primer may inco ⁇ orate flanking (selected) restriction enzyme sites.
  • the product is then digested with those selected restriction enzymes and subcloned into the expression vector.
  • Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold virus DNA (Pharmingen) into Spodoptera frugiperda ("Sf9”) cells (ATCC CRL 1711) using lipofectin
  • viruses are harvested and used for further amplifications.
  • Viral infection and protein expression are performed as described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual. Oxford: Oxford University Press (1994).
  • Expressed poly-His tagged PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can then be purified, for example, by Ni -chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature. 362:175- 179 (1993).
  • Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl 2 ; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KC1), and sonicated twice for 20 seconds on ice.
  • the sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 ⁇ m filter.
  • a Ni 2+ -NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A20 Q with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching A2g ⁇ baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer.
  • a secondary wash buffer 50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0
  • PR0211, PRO230, PR0261, PR0246, or EBAF-2 are pooled and dialyzed against loading buffer.
  • PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.
  • PR0187 (UNQ161); PR0533 (UNQ334); PR0214 (UNQ188); PRO240 (UNQ214); PR0211 (UNQ185); PRO230 (UNQ204); PR0246 (UNQ220); and EBAF-2 (UNQ278) were expressed in baculovirus infected Sf9 insect cells. While the expression was actually performed in a 0.5-2 L scale, it can be readily scaled up for larger (e.g. 8 L) preparations.
  • the proteins were expressed as an IgG construct (immunoadhesin), in which the protein extracellular region was fused to an IgGl constant region sequence containing the hinge, CH2 and CH3 domains and/or in poly-His tagged forms.
  • baculovirus expression vector pb.PH.lgG for IgG fusions and pb.PH.His.c for poly-His tagged proteins
  • vector and Baculogold® baculovirus DNA were co-transfected into 105 Spodoptera frugiperda ("Sf9") cells (ATCC CRL 1711), using Lipofectin (Gibco BRL).
  • Sf9 Spodoptera frugiperda
  • pb.PH.lgG and pb.PH.His are modifications of the commercially available baculovirus expression vector pVL 1393 (Pharmingen), with modified polylinker regions to include the His or Fc tag sequences.
  • the cells were grown in Hink's TNM-FH medium supplemented with 10% FBS (Hyclone). Cells were incubated for 5 days at 28°C. The supernatant was harvested and subsequently used for the first viral amplification by infecting Sf9 cells in Hink's TNM-FH medium supplemented with 10% FBS at an approximate multiplicity of infection (MOI) of 10. Cells were incubated for 3 days at 28°C.
  • MOI multiplicity of infection
  • the supernatant was harvested and the expression of the constructs in the baculovirus expression vector was determined by batch binding of 1 ml of supernatant to 25 mL of Ni-NTA beads (QIAGEN) for histidine tagged proteins or Protein-A Sepharose CL-4B beads (Pharmacia) for IgG tagged proteins followed by SDS-PAGE analysis comparing to a known concentration of protein standard by Coomassie blue staining.
  • the first viral amplification supernatant was used to infect a spinner culture (500 ml) of Sf9 cells grown in ESF-921 medium (Expression Systems LLC) at an approximate MOI of 0.1. Cells were incubated for 3 days at 28°C. The supernatant was harvested and filtered. Batch binding and SDS-PAGE analysis was repeated, as necessary, until expression of the spinner culture was confirmed.
  • the conditioned medium from the transfected cells (0.5 to 3 L) was harvested by centrifugation to remove the cells and filtered through 0.22 micron filters.
  • the protein construct were purified using a Ni-NTA column (Qiagen). Before purification, imidazole was added to the conditioned media to a concentration of 5 mM. The conditioned media were pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C.
  • the column was washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole.
  • the highly purified protein was subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.
  • Immunoadhesin (Fc containing) constructs of proteins were purified from the conditioned media as follows.
  • the conditioned media were pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column was washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5.
  • the eluted protein was immediately neutralized by collecting 1 ml fractions into tubes containing 275 mL of 1 M Tris buffer, pH 9.
  • the highly purified protein was subsequently desalted into storage buffer as described above for the poly-His tagged proteins.
  • the homogeneity of the proteins was verified by SDS polyacrylamide gel (PEG) electrophoresis and N-terminal amino acid sequencing by Edman degradation.
  • EXAMPLE 9 Demonstration of binding of PRQ533 (UNQ3341 to FGF Receptor 3 PR0533 was expressed in baculovirus in a C-terminal His8 epitope tagged form as described in Example 8, as was a control C-terminal His8 epitope protein.
  • Proteins were allowed to interact in binding buffer (DMEM media + lOmM Hepes pH 7.4 + 0.1% albumin + 200 ng/ml heparin) at room temperature for one hour. Protein A Sepharose (Pharmacia) was added (0.01 ml) and binding continued for 30 minutes.
  • Protein A Sepharose beads were collected and washed twice in binding buffer. Samples were then resolved by SDS PAGE under reducing conditions. Western blot analysis was conducted with anti-His antibody (Qiagen) as recommended by manufacturer. The results are shown in Figure 4. The specific binding components are as indicated above lanes 1-8 in Figure 4. Lane 9 contains PR0533-His (UNQ334-His) loaded directly onto gel for comparison. The position of the molecular weight markers is indicated on the left side of the gel for comparison.
  • PRQ246 or EBAF-2
  • This example illustrates preparation of monoclonal antibodies which can specifically bind PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2.
  • Immunogens that may be employed include purified PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2, fusion proteins containing PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2, and cells expressing recombinant PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.
  • mice such as Balb/c are immunized with the PRO 187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms.
  • the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads.
  • the immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections.
  • Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 antibodies.
  • the animals "positive" for antibodies can be injected with a final intravenous injection of PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2.
  • the mice are sacrificed and the spleen cells are harvested.
  • the spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.l, available from ATCC, No. CRL 1597.
  • the fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.
  • HAT hyperxanthine, aminopterin, and thymidine
  • hybridoma cells will be screened in an ELISA for reactivity against PROl 87, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, orEBAF-2. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261, PR0246, or EBAF-2 is within the skill in the art.
  • the positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PR0187, PR0533, PR0214, PRO240, PR0211, PRO230, PR0261,
  • the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à des compositions et à des méthodes permettant de diagnostiquer et de traiter la croissance et la prolifération cellulaires néoplasiques chez les mammifères, et notamment chez l'homme. L'invention est fondée sur l'identification de gènes qui sont amplifiés dans le génome de cellules tumorales. Une telle amplification de gènes devrait être associée à la surexpression du produit génique et devrait contribuer à la formation de tumeurs. Conformément à la présente invention, les protéines codées par les gènes amplifiés devraient être des cibles utiles pour le diagnostic et/ou le traitement (y compris la prévention) de certains cancers, et devraient pouvoir jouer le rôle de prédicteurs pour le pronostic de traitement des tumeurs.
PCT/US1998/018824 1994-09-08 1998-09-10 Genes amplifies dans des tumeurs, anticorps diriges contre les proteines codees par ces genes, et leur utilisation dans le diagnostic et le traitement du cancer WO1999014327A2 (fr)

Priority Applications (231)

Application Number Priority Date Filing Date Title
AU93121/98A AU9312198A (en) 1997-09-17 1998-09-10 Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
JP2000570204A JP2003524380A (ja) 1998-09-10 1999-09-08 腫瘍治療のための組成物及び方法
CA002341304A CA2341304A1 (fr) 1998-09-10 1999-09-08 Compositions et methodes de traitement des tumeurs
PCT/US1999/020594 WO2000015666A2 (fr) 1998-09-10 1999-09-08 Compositions et methodes de traitement des tumeurs
IL14142699A IL141426A0 (en) 1998-09-10 1999-09-08 Compositions and methods for the treatment of tumor
AU58167/99A AU5816799A (en) 1998-09-10 1999-09-08 Compositions and methods for the treatment of tumor
EP99945592A EP1109833A2 (fr) 1998-09-10 1999-09-08 Compositions et methodes de traitement des tumeurs
KR1020017003085A KR20010103576A (ko) 1998-09-10 1999-09-08 종양 치료용 조성물 및 치료 방법
MXPA01002545A MXPA01002545A (es) 1998-09-10 1999-09-08 Composiciones y metodos para el tratamiento de tumores.
US09/828,366 US20020010137A1 (en) 1997-09-18 2001-04-05 Methods and compositions for inhibiting neoplastic cell growth
US09/902,692 US20030054400A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,634 US20030082540A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,572 US20030108983A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,736 US20030049676A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,615 US20030092002A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,853 US20020192659A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,979 US20030113718A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,713 US20030082541A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,759 US20030077654A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/902,903 US20030044839A1 (en) 1997-09-17 2001-07-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,562 US6965015B2 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,603 US20030148419A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,943 US20030054349A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,640 US7208308B2 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,786 US20030044793A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,520 US20030054401A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,806 US20030130489A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,119 US20030049621A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids enconding the same
US09/903,925 US20030096233A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/903,749 US7147853B2 (en) 1997-09-17 2001-07-11 Anti-pro211 polypeptide antibodies
US09/903,823 US20030104381A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,011 US20030003530A1 (en) 1997-09-17 2001-07-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,938 US20030211569A1 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,786 US7557192B2 (en) 1997-09-17 2001-07-12 Anti-PRO335 antibodies
US09/905,125 US6664376B2 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,088 US20030073077A1 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,859 US20030036060A1 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,056 US20030054441A1 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,992 US20030135025A1 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,291 US20020160374A1 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,877 US20030186358A1 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,766 US20030152999A1 (en) 1997-09-17 2001-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,838 US20030148370A1 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,075 US7169906B2 (en) 1997-09-17 2001-07-13 PRO211 polypeptides
US09/904,553 US20030059828A1 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,462 US6878807B2 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,532 US7151160B2 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,449 US6965011B2 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,920 US6806352B2 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,348 US20030064923A1 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,820 US20030036094A1 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/905,381 US6818746B2 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,485 US20030064367A1 (en) 1997-09-17 2001-07-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/904,956 US20030049622A1 (en) 1995-12-01 2001-07-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,646 US6852848B2 (en) 1997-09-17 2001-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,700 US6723535B2 (en) 1997-09-17 2001-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,760 US20030096340A1 (en) 1997-09-17 2001-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,679 US6974689B1 (en) 1997-09-18 2001-07-16 Nucleic acid encoding PRO211 polypeptides
US09/906,742 US20030023054A1 (en) 1997-09-17 2001-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,777 US20030148371A1 (en) 1997-09-17 2001-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,815 US7094567B2 (en) 1997-09-17 2001-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,838 US7070979B2 (en) 1997-09-17 2001-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/906,618 US6828146B2 (en) 1997-09-17 2001-07-16 Nucleic acid encoding PRO229 polypeptides
US09/906,722 US6946262B2 (en) 1997-09-17 2001-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,925 US20030054352A1 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,728 US20030190611A1 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,979 US20030082542A1 (en) 1994-09-08 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/908,093 US20030017498A1 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,613 US20030027145A1 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,824 US20020197671A1 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,575 US20030073079A1 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,841 US7033825B2 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,652 US20030104469A1 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,942 US7087738B2 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/907,794 US6635468B2 (en) 1997-09-17 2001-07-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/909,204 US20030036061A1 (en) 1997-09-17 2001-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/908,576 US20040005553A1 (en) 1997-09-17 2001-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/909,088 US20020146709A1 (en) 1997-09-17 2001-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/909,320 US7074592B2 (en) 1997-09-17 2001-07-18 Secreted and transmembrane polypeptides nucleic acid encoding
US09/909,064 US6818449B2 (en) 1997-09-17 2001-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/002,796 US20030032057A1 (en) 1997-08-26 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/001,054 US20020192209A1 (en) 1997-09-17 2001-11-30 Methods and compositions for inhibiting neoplastic cell growth
US10/028,072 US20030004311A1 (en) 1997-06-18 2001-12-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,203 US20030180796A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,500 US20020177165A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding
US10/066,269 US20030040014A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,198 US20030170721A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,273 US7317092B2 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,211 US20030044844A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/081,056 US20040043927A1 (en) 1997-09-19 2002-02-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US10/119,480 US20040087769A1 (en) 1998-09-10 2002-04-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,046 US20030194791A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,059 US20030190721A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,045 US20030073210A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,047 US20030077778A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,042 US20030096386A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,040 US20030082759A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,044 US20030190717A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,051 US20030092147A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,041 US20030077776A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,056 US20030082760A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,061 US20030082761A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,062 US20030077779A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,052 US20030199052A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,063 US20030199055A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,050 US20030054516A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,055 US20030190718A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,057 US20030190719A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,058 US20030190720A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,048 US20030199051A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,054 US20030199054A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,053 US20030199053A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,043 US7220831B2 (en) 1997-03-31 2002-04-12 PRO235 polypeptides
US10/121,049 US20030022239A1 (en) 1997-06-18 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,060 US20030190722A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,236 US20030068795A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,155 US20030068794A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,771 US20030199060A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,213 US7193048B2 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,108 US7635478B2 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,214 US7343721B2 (en) 1997-03-31 2002-04-15 PRO4406 polypeptide
US10/123,157 US20030190725A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,213 US20030199057A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,322 US20030199059A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,156 US20030194792A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,215 US7291329B2 (en) 1997-03-31 2002-04-15 Antibodies against PRO4406
US10/123,235 US20030082762A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,291 US20030199058A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,212 US7276577B2 (en) 1997-03-31 2002-04-15 PRO1866 polypeptides
US10/123,154 US20030190724A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,261 US20030068796A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,262 US20030049816A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,109 US20030190723A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,292 US20030073211A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,909 US7193049B2 (en) 1997-03-31 2002-04-16 PRO862 polypeptides
US10/123,910 US7329404B2 (en) 1997-03-31 2002-04-16 Antibodies against PRO1310
US10/123,906 US20030190726A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,902 US20030077781A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,904 US20030022328A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,913 US20030203462A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,905 US20030087344A1 (en) 1997-06-18 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,903 US20030073212A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,907 US7084258B2 (en) 1997-03-31 2002-04-16 Antibodies against the PRO862 polypeptides
US10/123,905 US7285625B2 (en) 1997-06-18 2002-04-16 PRO536 polypeptides
US10/123,912 US20030100087A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,908 US7335728B2 (en) 1997-03-31 2002-04-16 PRO1310 polypeptides
US10/123,911 US7408032B2 (en) 1997-03-31 2002-04-16 PRO1188 polypeptides
US10/124,814 US7105335B2 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,821 US20030199023A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,817 US20030077786A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,805 US20030194794A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,704 US7357926B2 (en) 1997-03-31 2002-04-17 Antibodies against PRO1879 and the use thereof
US10/124,819 US7285626B2 (en) 1997-03-31 2002-04-17 PRO1076 polypeptides
US10/124,823 US20030199062A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,818 US20030082763A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,822 US7109305B2 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,820 US20030190729A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,795 US7304131B2 (en) 1997-03-31 2002-04-17 PRO1483 polypeptides
US10/124,824 US20030077659A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,816 US20030190728A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,813 US7312307B2 (en) 1997-03-31 2002-04-17 PRO1056 polypeptides
US10/125,924 US7342097B2 (en) 1997-03-31 2002-04-19 PRO1309 polypeptides
US10/125,922 US7309762B2 (en) 1997-03-31 2002-04-19 PRO1360 polypeptides
US10/125,931 US20030199063A1 (en) 1997-03-31 2002-04-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,927 US20030190731A1 (en) 1997-03-31 2002-04-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,932 US7317079B2 (en) 1997-03-31 2002-04-19 PRO812 polypeptides
US10/127,831 US20030082689A1 (en) 1997-03-31 2002-04-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/128,689 US20030087365A1 (en) 1997-03-31 2002-04-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/131,817 US7291701B2 (en) 1997-03-31 2002-04-24 PRO1777 polypeptides
US10/131,825 US7282566B2 (en) 1997-03-31 2002-04-24 PRO1779 polypeptide
US10/131,823 US7304132B2 (en) 1997-03-31 2002-04-24 PRO1693 polypeptides
US10/137,865 US20030032155A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/137,868 US20030082764A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/137,867 US20030207349A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,023 US20030207416A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/139,980 US7247710B2 (en) 1997-03-31 2002-05-06 PRO4395 antibodies
US10/140,020 US20030207415A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/139,963 US7288625B2 (en) 1997-03-31 2002-05-06 PRO4395 polypeptides
US10/140,024 US20040058424A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,470 US20030022331A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,474 US20030032156A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,860 US7307151B2 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,921 US7317080B2 (en) 1997-03-31 2002-05-07 PRO4303 polypeptides
US10/140,925 US20030073215A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,928 US20030068798A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,809 US20030207418A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,864 US20030207419A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,805 US20030207417A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,808 US7425621B2 (en) 1997-03-31 2002-05-07 Antibodies against the PRO4401 polypeptide
US10/140,865 US20030207420A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,760 US7342104B2 (en) 1997-03-31 2002-05-08 Antibodies against the PRO4320 polypeptide
US10/141,701 US20030207421A1 (en) 1997-03-31 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,754 US7361732B2 (en) 1997-03-31 2002-05-08 PRO4400 polypeptides
US10/141,755 US7297764B2 (en) 1997-03-31 2002-05-08 PRO4318 polypeptides
US10/141,756 US7488586B2 (en) 1997-03-31 2002-05-08 PRO4409 polypeptides
US10/142,425 US20030207424A1 (en) 1997-03-31 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/142,417 US7304133B2 (en) 1997-03-31 2002-05-09 PRO4389 polypeptides
US10/142,430 US7309766B2 (en) 1997-03-31 2002-05-09 PRO5774 polypeptides
US10/143,114 US20030036180A1 (en) 1997-03-31 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/143,113 US7329730B2 (en) 1997-03-31 2002-05-09 PRO4348 polypeptides
US10/142,419 US7153941B2 (en) 1997-03-31 2002-05-10 Antibodies that bind PRO4994 polypeptides
US10/143,032 US7408033B2 (en) 1997-03-31 2002-05-10 PRO5995 polypeptides
US10/142,431 US7285629B2 (en) 1997-03-31 2002-05-10 Pro5005 polypeptides
US10/142,423 US20030049817A1 (en) 1997-03-31 2002-05-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/146,730 US20030207427A1 (en) 1997-03-31 2002-05-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/146,792 US20030207428A1 (en) 1997-03-31 2002-05-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,528 US20030219885A1 (en) 1997-03-31 2002-05-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,536 US20040077064A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,492 US20030082765A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,519 US20030077791A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/152,395 US7189534B2 (en) 1997-03-31 2002-05-21 PRO4320 polynucleotide
US10/153,934 US20030129695A1 (en) 1997-03-31 2002-05-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/156,843 US20030207805A1 (en) 1997-06-18 2002-05-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/157,786 US20030208055A1 (en) 1997-03-31 2002-05-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/157,782 US20030077792A1 (en) 1997-03-31 2002-05-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/160,498 US20030073216A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/158,791 US20030207429A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/158,782 US20030082766A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,913 US20030022298A1 (en) 1997-09-15 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,942 US20030175882A1 (en) 1998-09-10 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/215,371 US20040137561A1 (en) 1997-10-17 2002-08-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/963,467 US7223586B2 (en) 1997-09-18 2004-10-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/970,823 US7307152B2 (en) 1997-10-17 2004-10-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/050,559 US7157267B2 (en) 1997-10-17 2005-02-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/080,062 US7619062B2 (en) 1997-10-17 2005-03-14 PRO214 polypeptides
US11/081,485 US20050170465A1 (en) 1997-10-17 2005-03-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/240,891 US20060246540A1 (en) 1997-08-26 2005-09-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/341,175 US7468427B2 (en) 1997-03-31 2006-01-27 Antibodies to PRO1275 polypeptide
US11/353,554 US7417126B2 (en) 1997-10-17 2006-02-13 PRO246 antibodies
US11/355,441 US7449551B2 (en) 1997-09-18 2006-02-15 PRO211 polypeptides
US11/518,609 US20070077623A1 (en) 1997-09-17 2006-09-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US5911797P 1997-09-17 1997-09-17
US5911497P 1997-09-17 1997-09-17
US60/059,117 1997-09-17
US60/059,114 1997-09-17
US5926397P 1997-09-18 1997-09-18
US6212597P 1997-10-15 1997-10-15
US6228797P 1997-10-17 1997-10-17
US6228597P 1997-10-17 1997-10-17
US6281697P 1997-10-24 1997-10-24
US6370497P 1997-10-29 1997-10-29
US60/063,704 1997-10-29
US6684097P 1997-11-25 1997-11-25
US60/059,263 1997-11-25
US60/062,816 1997-11-25
US60/062,287 1997-11-25
US60/062,125 1997-11-25
US60/066,840 1997-11-25
US60/062,285 1997-11-25

Related Child Applications (13)

Application Number Title Priority Date Filing Date
PCT/US1998/019177 Continuation-In-Part WO1999014234A2 (fr) 1994-09-08 1998-09-14 Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US1998/019093 Continuation-In-Part WO1999015653A2 (fr) 1997-03-31 1998-09-14 Homologues du ligand 'tie'
PCT/US1998/019330 Continuation-In-Part WO1999014328A2 (fr) 1994-09-08 1998-09-16 Polypeptides secretes et transmembranaires et acides nucleiques les codant
US18099798A A-371-Of-International 1997-08-26 1998-11-19
PCT/US1998/025108 Continuation-In-Part WO1999028462A2 (fr) 1994-09-08 1998-12-01 Polypeptides et acides nucleiques codant ces derniers
PCT/US1999/028313 Continuation-In-Part WO2000032221A2 (fr) 1994-09-08 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
PCT/US2000/004414 Continuation-In-Part WO2001004311A1 (fr) 1994-09-08 2000-02-22 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US66535000A Continuation-In-Part 1994-09-08 2000-09-18
US66535000A Continuation 1994-09-08 2000-09-18
US09/903,749 Continuation US7147853B2 (en) 1997-09-17 2001-07-11 Anti-pro211 polypeptide antibodies
US10/081,056 Continuation US20040043927A1 (en) 1997-09-19 2002-02-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US10/119,480 Continuation US20040087769A1 (en) 1998-09-10 2002-04-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,942 Continuation US20030175882A1 (en) 1998-03-27 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (2)

Publication Number Publication Date
WO1999014327A2 true WO1999014327A2 (fr) 1999-03-25
WO1999014327A3 WO1999014327A3 (fr) 1999-09-30

Family

ID=27578244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018824 WO1999014327A2 (fr) 1994-09-08 1998-09-10 Genes amplifies dans des tumeurs, anticorps diriges contre les proteines codees par ces genes, et leur utilisation dans le diagnostic et le traitement du cancer

Country Status (2)

Country Link
AU (1) AU9312198A (fr)
WO (1) WO1999014327A2 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015666A2 (fr) * 1998-09-10 2000-03-23 Genentech, Inc. Compositions et methodes de traitement des tumeurs
WO2000015792A2 (fr) * 1998-09-14 2000-03-23 Genentech, Inc. Promotion ou inhibition d'angiogenese et de cardiovascularisation
WO2000017236A2 (fr) * 1998-09-24 2000-03-30 Millennium Pharmaceuticals, Inc. Proteines reliees a l'apoptose et utilisations associees
WO2000021996A2 (fr) * 1998-10-13 2000-04-20 Genentech, Inc. Procedes et compositions inhibant la croissance des cellules neoplasiques
WO2000055319A1 (fr) * 1999-03-12 2000-09-21 Genentech, Inc. Procedes et compositions pour inhiber la croissance des cellules neoplasiques
WO2000073348A2 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
WO2001004311A1 (fr) * 1999-07-07 2001-01-18 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
WO2001005836A1 (fr) * 1999-07-20 2001-01-25 Genentech, Inc. Compositions polypeptidiques et methodes de traitement des tumeurs
WO2001018210A1 (fr) * 1999-09-08 2001-03-15 Genentech, Inc. Acides nucleiques et polypeptides du facteur 19 de croissance du fibroblaste, et procedes d'utilisation dans le traitement de l'obesite
WO2001019987A1 (fr) * 1999-09-13 2001-03-22 Genentech, Inc. Promotion ou inhibition de l'angiogenese et de la vascularisation cardiaque
WO2001025427A1 (fr) * 1999-10-01 2001-04-12 Kyowa Hakko Kogyo Co., Ltd. Adn reagissant a la contrainte de cisaillement
EP1185642A2 (fr) * 1999-06-09 2002-03-13 Genentech, Inc. Compositions et methodes de traitement de tumeur
US6368822B1 (en) 1995-06-05 2002-04-09 Human Genome Sciences, Inc. Fibroblast growth factor 13
US6403557B1 (en) 1996-11-27 2002-06-11 Human Genome Sciences, Inc. Fibroblast growth factor-13
AU783117B2 (en) * 1999-09-08 2005-09-29 Genentech Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US6960651B2 (en) 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
US6974689B1 (en) 1997-09-18 2005-12-13 Genentech, Inc. Nucleic acid encoding PRO211 polypeptides
EP1690873A2 (fr) * 1999-12-01 2006-08-16 Genentech, Inc. Composition et procédés de diagnostic de tumeurs
US7147853B2 (en) 1997-09-17 2006-12-12 Genentech, Inc. Anti-pro211 polypeptide antibodies
US7169906B2 (en) 1997-09-17 2007-01-30 Genentech, Inc. PRO211 polypeptides
EP1032668B1 (fr) * 1997-11-25 2008-05-28 Genentech, Inc. Facteur de croissance des fibroblastes 19
EP2014770A3 (fr) * 1997-10-29 2009-02-18 Genentech, Inc. Polypeptide secrété à induction par WNT-1 WISP-2
US7695962B2 (en) 1997-10-29 2010-04-13 Genentech, Inc. Polypeptides and nucleic acids encoding same
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
US7737257B2 (en) 1996-11-08 2010-06-15 Human Genome Sciences, Inc. Connective tissue growth factor (CTGF-3)
US7771930B2 (en) 2001-06-27 2010-08-10 Cancer Research Technology Limited Cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020238A2 (fr) * 1992-04-07 1993-10-14 The Johns Hopkins University Amplification du gene mdm2 dans des tumeurs chez l'homme
WO1994000603A1 (fr) * 1992-06-26 1994-01-06 The Trustees Of Princeton University Procede de detection de cellules precancereuses ou cancereuses au moyen d'anticorps ou de sondes de p90
WO1996038509A1 (fr) * 1995-05-31 1996-12-05 Nocopi Technologies, Inc. Procede et compositions d'authentification d'un produit ou d'un document
WO1996039508A1 (fr) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Facteur de croissance des fibroblastes 13

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020238A2 (fr) * 1992-04-07 1993-10-14 The Johns Hopkins University Amplification du gene mdm2 dans des tumeurs chez l'homme
WO1994000603A1 (fr) * 1992-06-26 1994-01-06 The Trustees Of Princeton University Procede de detection de cellules precancereuses ou cancereuses au moyen d'anticorps ou de sondes de p90
WO1996038509A1 (fr) * 1995-05-31 1996-12-05 Nocopi Technologies, Inc. Procede et compositions d'authentification d'un produit ou d'un document
WO1996039508A1 (fr) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Facteur de croissance des fibroblastes 13

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368822B1 (en) 1995-06-05 2002-04-09 Human Genome Sciences, Inc. Fibroblast growth factor 13
US7208584B2 (en) * 1995-06-05 2007-04-24 Human Genome Sciences, Inc. Fibroblast growth factor-13
US7994284B2 (en) 1996-11-08 2011-08-09 Human Genome Sciences, Inc. Connective tissue growth factor (CTGF-3) polypeptides
US7737257B2 (en) 1996-11-08 2010-06-15 Human Genome Sciences, Inc. Connective tissue growth factor (CTGF-3)
US6403557B1 (en) 1996-11-27 2002-06-11 Human Genome Sciences, Inc. Fibroblast growth factor-13
US7169906B2 (en) 1997-09-17 2007-01-30 Genentech, Inc. PRO211 polypeptides
US7147853B2 (en) 1997-09-17 2006-12-12 Genentech, Inc. Anti-pro211 polypeptide antibodies
US7223586B2 (en) 1997-09-18 2007-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6974689B1 (en) 1997-09-18 2005-12-13 Genentech, Inc. Nucleic acid encoding PRO211 polypeptides
US7449551B2 (en) 1997-09-18 2008-11-11 Genentech, Inc. PRO211 polypeptides
US8350008B2 (en) 1997-10-29 2013-01-08 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
US7695962B2 (en) 1997-10-29 2010-04-13 Genentech, Inc. Polypeptides and nucleic acids encoding same
EP2014770A3 (fr) * 1997-10-29 2009-02-18 Genentech, Inc. Polypeptide secrété à induction par WNT-1 WISP-2
EP1032668B1 (fr) * 1997-11-25 2008-05-28 Genentech, Inc. Facteur de croissance des fibroblastes 19
WO2000015666A3 (fr) * 1998-09-10 2000-11-23 Genentech Inc Compositions et methodes de traitement des tumeurs
WO2000015666A2 (fr) * 1998-09-10 2000-03-23 Genentech, Inc. Compositions et methodes de traitement des tumeurs
WO2000015792A3 (fr) * 1998-09-14 2000-09-21 Genentech Inc Promotion ou inhibition d'angiogenese et de cardiovascularisation
WO2000015792A2 (fr) * 1998-09-14 2000-03-23 Genentech, Inc. Promotion ou inhibition d'angiogenese et de cardiovascularisation
WO2000017236A2 (fr) * 1998-09-24 2000-03-30 Millennium Pharmaceuticals, Inc. Proteines reliees a l'apoptose et utilisations associees
WO2000017236A3 (fr) * 1998-09-24 2000-05-25 Millennium Pharm Inc Proteines reliees a l'apoptose et utilisations associees
WO2000021996A3 (fr) * 1998-10-13 2000-11-09 Genentech Inc Procedes et compositions inhibant la croissance des cellules neoplasiques
WO2000021996A2 (fr) * 1998-10-13 2000-04-20 Genentech, Inc. Procedes et compositions inhibant la croissance des cellules neoplasiques
WO2000055319A1 (fr) * 1999-03-12 2000-09-21 Genentech, Inc. Procedes et compositions pour inhiber la croissance des cellules neoplasiques
WO2000073348A3 (fr) * 1999-06-02 2001-07-05 Genentech Inc Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
WO2000073348A2 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
EP1185642A2 (fr) * 1999-06-09 2002-03-13 Genentech, Inc. Compositions et methodes de traitement de tumeur
US6960651B2 (en) 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
US8076086B2 (en) 1999-06-29 2011-12-13 Millennium Pharmaceuticals, Inc. Methods of modulating the activity of TANGO332
WO2001004311A1 (fr) * 1999-07-07 2001-01-18 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
WO2001005836A1 (fr) * 1999-07-20 2001-01-25 Genentech, Inc. Compositions polypeptidiques et methodes de traitement des tumeurs
AU783117B2 (en) * 1999-09-08 2005-09-29 Genentech Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
WO2001018210A1 (fr) * 1999-09-08 2001-03-15 Genentech, Inc. Acides nucleiques et polypeptides du facteur 19 de croissance du fibroblaste, et procedes d'utilisation dans le traitement de l'obesite
WO2001019987A1 (fr) * 1999-09-13 2001-03-22 Genentech, Inc. Promotion ou inhibition de l'angiogenese et de la vascularisation cardiaque
WO2001025427A1 (fr) * 1999-10-01 2001-04-12 Kyowa Hakko Kogyo Co., Ltd. Adn reagissant a la contrainte de cisaillement
EP1690872A2 (fr) * 1999-12-01 2006-08-16 Genentech, Inc. Composition et procédés de diagnostic de tumeurs
EP1690873A2 (fr) * 1999-12-01 2006-08-16 Genentech, Inc. Composition et procédés de diagnostic de tumeurs
US7771930B2 (en) 2001-06-27 2010-08-10 Cancer Research Technology Limited Cancer
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method

Also Published As

Publication number Publication date
AU9312198A (en) 1999-04-05
WO1999014327A3 (fr) 1999-09-30

Similar Documents

Publication Publication Date Title
EP1626058B1 (fr) Compositions et méthodes pour le diagnostique de tumeurs
US20080175842A1 (en) Compositions and methods for treatment
WO1999014327A2 (fr) Genes amplifies dans des tumeurs, anticorps diriges contre les proteines codees par ces genes, et leur utilisation dans le diagnostic et le traitement du cancer
JP4260778B2 (ja) 腫瘍の治療のための組成物と方法
US6326482B1 (en) SH2 domain-containing peptides
US7173115B2 (en) Stra6 polypeptides
EP1109833A2 (fr) Compositions et methodes de traitement des tumeurs
US20030191283A1 (en) Nsp molecules
US6472585B1 (en) Cardiotrophin-1 defective mouse
EP1145011B1 (fr) Compositions et procedes de traitement de tumeurs
US7258983B2 (en) Cardiotrophin-1 compositions and methods for the treatment of tumor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09180997

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase in:

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载